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General introduction
General introduction
Worldwide, stroke is the fourth most common cause of death behind disease of the heart, 
cancer and chronic lower respiratory disease. 1  Between 1998 and 2008 the annual stroke 
death rate decreased 35%, but still stroke is a leading cause of serious long-term disability. 
1  Most patients suffer from physical disability, but one third of patients also suffers from 
psychiatric symptoms like depression. 2  In the Netherlands, the annual incidence of stroke 
is estimated to be 41.000, while about 300.000 persons live with the consequence of a 
stroke. 3,4  In 2011, stroke is the third most common cause of death in the Netherlands in 
men (5.2%), after pulmonary carcinoma (9.9%) and ischemic heart disease (5.8%). In 
women stroke is the most common cause of death (7.7%), before pulmonary carcinoma 
(5.2%) and carcinoma of the breast (4.6%). 5  In the past decades the mortality rate of 
stroke in the Netherlands has declined from approximately 10% for men and 15% for 
women in 1970 to approximately 5% and 8% in 2010. 5  Also, the mortality rate in the ﬁrst 
year after a stroke has declined with approximately a quarter between 2000 and 2005, 
because of more adjusted treatment in the acute phase and more attention to stroke 
services. 6 
Despite this reduction in stroke mortality and a decrease in stroke incidence, due to 
primary and secondary prevention, an increase in the prevalence and burden of stroke is to 
be expected, considering the growth of the total elderly population and the general 
improvements in life expectancy. 7,8  Therefore, it is important to continue and to improve 
prevention strategies. Additionally, to reduce the burden of stroke it is also important to 
explore novel strategies that reduce disability after stroke, particularly development of 
novel treatment options and improvement of currently available treatments.
Revascularization therapy
The development of revascularization therapy with recombinant tissue plasminogen 
activator (tPA) has shown great beneﬁt in improving outcome and reducing disability in 
patients with acute ischemic stroke. 9-13  In the ﬁrst years of use, tPA treatment was registered 
as an effective treatment for acute ischemic stroke within 3 hours after symptom onset. 12  
The chances of beneﬁt from tPA treatment diminish as time elapses. Compared to controls 
the odds ratios of a favorable outcome for patients treated with tPA were 2.81 (1.75 – 4.50) 
for those treated within 90 minutes and 1.55 (1.12 – 2.15) for those treated within 91 and 
180 minutes of symptom onset. 12  In 2010, a pooled analysis of tPA trials showed that tPA 
treatment also improves the odds of a favorable outcome when looking at a treatment 
interval until 270 minutes after symptom onset. 13  Beyond the limit of 270 minutes the 
beneﬁts of tPA treatment may not outweigh the risks. 13  Overall, tPA treatment is the most 
effective when administrated in the ﬁrst 90 minutes after symptom onset, but despite all 
efforts it is still only effective in a minority of patients. In the patient group treated within 11
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90 minutes the number needed to treat (NNT) to achieve one excellent outcome (modiﬁed 
Rankin Scale 0-1, Table 1) is about 5, within 91-180 minutes of stroke onset the NNT it is 
9 and within 181-270 minutes it drops to 15. 13  
Table 1: Outcome measures following modiﬁed Rankin Scale (mRS)
Outcome measure Corresponding score Description
Excellent outcome mRS 0-1 No symptoms/no signiﬁcant disability
Good outcome mRS 0-2 Independence with regard tot activities of daily living, 
unable to carry out all previous activities
Poor outcome mRS 3-6 Dependence or death
The major risk associated with tPA treatment is the occurrence of symptomatic intracranial 
hemorrhage (SICH). Various trials report a signiﬁcant higher risk of SICH in tPA treated 
patients compared to non-treated patients, for instance 6.4% versus 0.6% 9 , 8.8% versus 
3.4% 11  and 7.0% versus 1.1% 14 . However, the Safe Implementation of Thrombolysis in 
Stroke-Monitoring Study (SITS-MOST) showed that the daily risk of SICH in routine 
practice is slightly lower than in the trials mentioned. 15 
Because of the relatively short time window, the number of patients who actually receive 
tPA treatment and therefore potentially beneﬁt, is small. Secondly, a number of contra-
indications for tPA treatment limits the actual eligibility of many patients to receive this 
treatment. Elevated serum glucose levels, elevated blood pressure levels and use of anti-
coagulation drugs are factors that increase the risk of complications of tPA treatment. 16 
Efforts to increase the number of patients eligible for thrombolytic therapy are made, for 
instance by improving the triage pathway and the public awareness,  in order to reduce 
onset-to-needle time.  17,18  Efforts are made to improve stroke treatment with new 
thrombolytics and endovascular treatment. 19,20  
Neuroprotection
Another therapeutic strategy to improve stroke outcome and reduce resulting disability is 
the development of neuroprotective agents. Neuroprotection refers to the effect of drugs or 
agents that prolong neuronal survival after ischemia. Compounds that block excitotoxicity 
have often been studied in this context. These agents are especially thought to protect the 
ischemic penumbra, a phenomenon which was ﬁrst introduced by Astrup in 1981. 21 The 
penumbra is a zone with markedly reduced blood ﬂow, with neurons that are functionally 
inactive but still viable. Saving the ischemic penumbra will lead to smaller infarct size and 
could lead to better recovery and functional outcome. In the absence of reperfusion or 
neuroprotection, the tissue in the ischemic penumbra undergoes also infarction.
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The neurons in the penumbra can stay viable within a time window of several hours as 
demonstrated by positron emission tomography (PET) and magnetic resonance imaging 
(MRI). 22-24  After several hours of ischemia the neurons are irreversibly damaged as a 
consequence of a cascade of biochemical events, called the ischemic cascade, in which 
calcium ion-inﬂux, intracellular calcium release and glutamate neurotoxicity play major 
roles. (Figure 1) 25,26  Reduction of blood ﬂow will lead to depletion of energy stores, failure 
of the sodium/potassium-pumps and, consequently, to massive depolarization. This 
depolarization causes release of large amounts of presynaptic glutamate. Under physiological 
conditions glutamate causes no neuronal damage, but in the state of ischemia excessive 
amounts of glutamate are neurotoxic. The acute elevation of glutamate will lead to activation 
of N-methyl-d-aspartate (NMDA) receptors and  -amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors and this, in turn, causes neuronal calcium inﬂux   
as well as release from intracellular calcium stores. Moreover, depolarization itself also 
causes an increase in intracellular calcium concentration. These elevated intracellular 
calcium concentrations cause irreversible damage by several mechanisms. Activation of 
proteases, lipases and caspases exerts detrimental effects on cellular function and membrane 
structure, ultimately leading to necrosis. Second, an increase in free radicals damages cell 
membranes. Finally, the resulting stimulation of intracellular processes increases oxygen 
demand and further worsening of the hypoxic state. 25,26 
Furthermore, the raised intracellular calcium concentrations and the increase of oxygen 
free radicals in ischemia trigger the expression of pro-inﬂammatory genes and thereby 
activate inﬂammatory processes. These inﬂammatory reactions have been suggested to 
contribute to the late stages of ischemic injury in worsening neurological outcome. 27,28 
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Several neuroprotective agents or therapies have been designed to try to salvage neurons 
within the penumbra. These therapies include calcium channel blockers, glutamate 
inhibitors and gamma-aminobutyric acid (GABA) agonists, free radical scavengers and 
hypothermia. Preclinical studies showed promising results, but all phase III clinical trials 
have failed to demonstrate positive clinical effects. 25,26,29-33  Various explanations for these 
disappointing results have been proposed.
A major cause are the methodological differences between animal models and clinical 
trials. In animal trials, the neuroprotective drugs are administered shortly before or after 
the ischemic event; in clinical trials these intervals are much larger. 25,30-32  It is hypothesized 
that in most clinical trials the administration would be too late to expect a meaningful 
neuroprotective effect. Another issue is the discrepancy between drug-dosing 
schedules. 25,30,31 In general, in clinical trials dosage regimens have been used that were 
lower and more variable than those used in animal experiments, to avoid possible adverse 
drug effects. A single dose may not provide sufﬁcient neuroprotection, while prolonged 
administration may also cause adverse effects. For instance, NMDA-antagonist may produce 
a neuroprotective effect in the early phase, but blockage can be detrimental in the later 
phases. NMDA activation is necessary for neurite outgrow that may play a role in recovery. 34  
Furthermore, heterogeneity of the study population plays a major role. In animal models 
strict physiological conditions with respect to blood pressure, temperature and oxygenation 
are maintained while the infarct type studied is mostly a cortical stroke by medial cerebral 
artery (MCA) occlusion. In the clinical trials these physiological conditions can not be 
standardized. In addition, patients suffer from other factors that inﬂuence prognosis, like 
age and co-morbidity. 25,30,31  Patients with cortical and lacunar strokes are often lumped 
together, but pathophysiological mechanisms between grey and white matter strokes may 
differ. Therefore, neuroprotective drugs could also act differently in these stroke subtypes. 35 
Finally, in most animal models efﬁcacy of the neuroprotective drug to be investigated was 
assessed by histological infarct size. In clinical trials, the effect of a neuroprotective drug is 
measured by using functional outcome scales. Infarct size has a poor correlation with 
outcome. Small infarcts in critical locations produce large deﬁcits while large infarcts in 
less eloquent locations may produce little detectable function loss. 25,30,31 
Hypothermia is a promising alternative in neuroprotection, having already shown beneﬁts 
in patients after cardiac arrest and perinatal asphyxia. 36  In animal models of cerebral 
ischemia it has consistently shown beneﬁt. 36-38  However, translation to clinical cerebral 
ischemic stroke has been less successful, partly because of issues like patient comfort and 
complications. 36-38 
In summary, factors that might be responsible for the failure of the development of 
neuroprotective agents are: the methodologies used,  insufﬁcient information about 
therapeutic doses and the therapeutic time window available. Moreover, the animal models 
used in these studies do not mimic the human clinical situation, particularly not the effects 
of infarct size and localization, nor the contribution of co-morbidity. 25,29-32 
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Combination therapies
Despite the disappointing results up to now, the prospect of neuroprotective agents remains 
tantalizing. Another research strategy is the combination of different treatments. As 
mentioned previously, several pathways in the ischemic cascade lead to increase of 
intracellular calcium and cell death. (Figure 1) A neuroprotective agent acts mostly on one 
speciﬁc pathway. A single neuroprotective agent may not be enough to result in a signiﬁcant 
clinical impact, as measured by functional outcome scales like the modiﬁed Rankin Scale 
(mRS) and the Barthel Index (BI). Therefore, it would be interesting to explore treatment 
options using either a combination of two or more neuroprotective agents or a combination 
of reperfusion therapy with a neuroprotective agent. 25,29-32,39  In animal models, evidence 
has been found for a positive interaction when combining tPA with a neuroprotective 
drug. 39-42  Treatment with tPA increases the chance of reperfusion in the ischemic penumbra 
and preserves salvageable tissue. Therefore, it may extend the therapeutic window for 
neuroprotective therapies. 41-43  Co-administration of neuroprotective drugs to tPA treatment 
might also extend the therapeutic window for tPA treatment. 44,45 Finally, combination of 
various neuroprotective drugs that target different aspects of the ischemic cascade could 
produce a synergistic effect. 31  But new trials using a combination of experimental drugs 
can be methodologically complex.
To summarize: combination therapies may not only improve outcome in patients with 
acute ischemic stroke, but they may also increase the amount of patients eligible for tPA 
treatment.
Aims and scope of the thesis
Reperfusion with tPA is the intervention of choice in acute ischemic stroke treatment to 
improve outcome, but as discussed before it is only possible in a selected group of acute 
ischemic stroke patients. It has several risks and contra-indications. Another approach to 
improve outcome after ischemic stroke is neuroprotection, with the aim to reduce secondary 
brain damage in the ischemic penumbra. Several treatment strategies targeting neurotoxic 
mechanisms that accompany acute brain ischemia have been explored, but in clinical 
settings these therapies have largely failed to even approach the beneﬁts that animal models 
had suggested. Preclinical studies also found evidence for positive treatment interactions 
when revascularization therapy and neuroprotective agents were combined.
In this thesis, the inﬂuence will be studied of two possible neuroprotective drug classes 
on functional outcome in tPA treated acute ischemic stroke patients. Furthermore, I will 
explore other prognostic factors that inﬂuence the therapeutic effects and safety of tPA 
treatment with regard to functional outcome and complications of revascularization 
therapy.
Chapter 2-4 describe the effects of possible neuroprotective agents and compounds on 
functional outcome. In Chapter 2 the effects on functional outcome of selective serotonin 
re-uptake inhibitors (SSRIs) that are being used prior to the ischemic stroke are examined. 15
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SSRIs are thought to be neuroprotective through their effects on neuronal cell survival and 
the plasticity of brain function. 46-48  The potential neuroprotective effect of prior statin use 
on functional outcome is studied in Chapter 3. Statins are widely used for the primary and 
secondary prevention of cardiovascular disease. They prevent ﬁrst as well as recurrent 
ischemic strokes mainly because of their lipid lowering effects. But they might have 
pleiotropic effects, amongst them neuroprotection in acute ischemic stroke. 49-51  Finally, the 
effects of serum uric acid concentrations on functional outcome are assessed (Chapter 4). 
Uric acid (UA) is a predictor for developing cardiovascular disease and stroke by 
mechanisms that are involved in the development and progression of atherosclerosis. It is 
also a powerful anti-oxidant and it could act as a free radical scavenger that reduces 
oxidative stress and protects the neurons in the ischemic penumbra. 52,53 
Admission hyperglycemia is common in patients with acute ischemic stroke. It is 
independently associated with poor functional outcome, in patients treated with and 
without intravenous tPA, regardless of a history of diabetes. 54-61  Previous studies in patients 
not treated with intravenous tPA found a dissociation of this harmful effect between lacunar 
and non-lacunar strokes, with a better outcome in hyperglycemic patients and lacunar 
stroke. 56,60 Chapter 5 explores the effects of hyperglycemia on functional outcome in tPA 
treated patients for both lacunar and non-lacunar strokes. 
There is much controversy whether to treat ischemic stroke patients with intravenous 
tPA when using a vitamin K antagonist (VKA) with an suboptimal international normalized 
ratio (INR). 62,63 In the ﬁrst part of Chapter 6 the relation between prior VKA use and a 
suboptimal INR with the occurrence of SICH and functional outcome is studied. The 
second part of Chapter 6 consists of a systematic review and meta-analysis of this subject. 
Finally, Chapter 7 presents a general discussion as well as the main conclusions of this 
thesis. 
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Abstract
Background 
Selective serotonin re-uptake inhibitors (SSRIs) may have therapeutic potential in the 
treatment of ischemic stroke by effects on neuronal cell survival and the plasticity of brain 
processes. In the present study, we investigated whether prior treatment with a SSRI is 
associated with more favorable functional outcome in a cohort of patients with acute 
ischemic stroke treated with tissue plasminogen activator (tPA).   
Methods 
In a prospective observational cohort study of 476 acute ischemic stroke patients treated 
with tPA we investigated the relationship between prior SSRI treatment and functional 
outcome at 3 months. Ischemic stroke subtypes were deﬁned according to the Oxfordshire 
Community Stroke Project Classiﬁcation. Favorable outcome was deﬁned as a modiﬁed 
Rankin Scale score 2. 
Results 
In the cohort of 476 patients, 22 (5%) patients used a SSRI at stroke onset. At 3 months, 
217 (46%) patients had a favorable outcome of whom 9 (41%) on SSRI treatment and 208 
(46%) not using SSRIs (p = 0.65). In a multivariable analysis SSRI treatment showed a 
trend to association with unfavorable outcome (OR 0.4, 95% CI 0.14-1.13, p = 0.08). In 
the 376 patients with cortical stroke, SSRI treatment was associated with a unfavorable 
outcome (OR 0.17, 95% CI 0.04-0.73, p = 0.017). 
Conclusion 
Our data suggest that in patients with acute ischemic stroke treated with tPA, prior SSRI 
use may be associated with a less favorable outcome, especially in cortical stroke. 23
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Introduction
The last two decades there is an increasing use of selective serotonin re-uptake inhibitors 
(SSRIs) in the treatment of depression and other psychiatric disorders. Depression also 
occurs in approximately 40% of acute stroke patients and has been signiﬁcantly linked to 
poor cognitive and physical recovery.  1,2  In patients who had a stroke, treatment with SSRIs 
after stroke improved cognitive and functional outcome.  3-5  In one study this effect was seen 
regardless of whether patients were initially depressed.  5  One way in which treatment with 
SSRIs may facilitate recovery of function in stroke patients is by improving mood and 
motivation to perform rehabilitation tasks.  3,5,6  Secondly, SSRIs could also have direct effects 
on neuronal cell survival and the plasticity of brain processes, for instance by modulation of 
neurotrophins, particularly brain-derived neurotrophic factor (BDNF). BDNF has a function 
as key regulator of neurite outgrowth, synaptic plasticity and the selection of functional 
neuronal connections. 7-9  Chronic administration of SSRIs enhances BDNF transcription. 
10,11  Furthermore, SSRIs also have effects on cerebral energy homeostasis and ion channel 
function. Altogether these data suggests that SSRIs might have therapeutic possibilities in 
several neurological disorders including ischemic stroke.  12,13  
Two clinical studies evaluating the effect of ﬂuoxetine on functional recovery of patients 
who had a stroke suggested an improvement in motor performance. 14,15  However, neither 
study included acute ischemic stroke patients. In the present study, we investigated whether 
prior treatment with a SSRI is associated with more favorable functional outcome in a 
cohort of patients with acute ischemic stroke treated with recombinant tissue plasminogen 
activator (tPA).  
Methods
An ongoing prospective registry of patients with acute ischemic stroke receiving tPA 
treatment was started at the University Medical Centre of Groningen in April 2002. All 
patients registered between April 2002 and March 2009 were included in this study. tPA 
treatment was performed within a time window of 4.5 hours after onset of symptoms 
according to a protocol which has been described earlier.  16  The neurological deﬁcit before 
tPA treatment was assessed according to the National Institute of Health Stroke Scale 
(NIHSS). Demographic and clinical information were recorded. Prior medication use, 
medication name and dosages were recorded for antiplatelet, lipid lowering and 
antidepressant drugs. During hospital stay and after discharge SSRI therapy was continued. 
We did not record how many patients using SSRI’s before stroke, stopped the treatment in 
the following 3 months after discharge. Furthermore, we did not document whether 
patients naive to SSRI’s started with a SSRI after discharge. Stroke subtypes were deﬁned 
into lacunar infarcts (LACI) and cortical infarcts (PACI and TACI) according to the 
Oxfordshire Community Stroke Project Classiﬁcation.  17 
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Outcome
The modiﬁed Rankin Scale (mRS) was used to determine functional outcome and was 
measured 3 months after stroke onset. Outcome was dichotomized into favorable outcome 
(mRS 0-2), corresponding to independence with regard to activities of daily living, and 
unfavorable outcome (mRS 3-6), reﬂecting death or dependency. Functional outcome was 
compared between patients with and without prior treatment with SSRIs. 
Statistics
Baseline characteristics for patients with or without prior treatment with SSRIs were 
compared. Mann Whitney U-test was used for continuous and ordinal variables without a 
normal distribution. Pearson’s Chi Square test and Fisher’s exact test were used for 
dichotomous variables. Variables within the univariable baseline characteristics for SSRI 
use and non SSRI use with a p value < 0.20 were selected as covariates for the multivariable 
logistic regression analysis. Regardless of the difference in baseline characteristics, age, 
NIHSS score and serum glucose level at presentation were entered in the multivariable 
analyses. These variables were considered to be possible confounders, since these variables 
are related to outcome in patients with acute ischemic stroke. Because of the aim of the 
study, SSRI therapy was also entered in the multivariable analysis. In the multivariable 
analysis with favorable outcome as dependent factor, variables with a p value > 0.20 were 
removed from the model. 
All statistical analyses were performed using SPSS 16.0. Statistical signiﬁcance was 
taken to be at two tailed level < 0.05. A binary logistic regression model was used for 
multivariable analysis, with adjustment for possible confounders, to calculate odds ratios 
with 95% conﬁdence interval.
Results
Patient sample
A total of 478 patients with acute ischemic stroke were treated with tPA within the study 
period. Data on functional outcome at 3 months were missing for 2 patients and they were 
excluded. In the cohort of 476 patients, 32 (7%) patients were using antidepressant drugs 
of which 22 (5%) patients were on a SSRI. Of the 22 patients with SSRI treatment, 8 
patients used paroxetine, 7 citalopram, 4 ﬂuoxetine, 2 venlafaxine and 1 patient 
escitalopram. Baseline characteristics of the entire cohort, SSRI users and patient not on a 
SSRI are shown in Table 1. Users of SSRIs were slightly younger than non users (64 vs 68 
years), but this difference was not signiﬁcant (p = 0.22). Women used more frequently a 
SSRI compared to men (73% vs 27%, p = 0.01). The presence of vascular risk factors at 
presentation and of infarct subtype did not signiﬁcantly differ between the two groups. 25
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Table 1:  Baseline characteristics entire cohort and (non) SSRI users 
Entire cohort SSRI user Non SSRI user
Characteristic N=476 N=22 N=454 P
Mean age (SD), years 68 (14) 64 (17) 68 (14) s
Male 257 (54) 6 (27) 251 (55) 0.010
Mean NIHSS score (SD)* 13 (6) 12 (5) 13 (6) s
Mean time until treatment (SD), min* 163 (50) 149 (44) 163 (50) s
Stroke subtype 0.807#
LACI 77 (16) 5 (23) 72 (16)
TACI 136 (29) 4 (18) 132 (29)
PACI 240 (51) 12 (55) 228 (50)
POCI 22 (5) 1 (5) 21 (5)
Early ischemic changes on brain CT scan 191 (40) 9 (41) 182 (40) 0.939
Hypodensity area > 33% on brain CT scan 29 (6) 1 (5) 28 (6) 1.000#
Vascular risk factors
Hypertension 220 (46) 10 (46) 210 (46) 0.941
Diabetes 62 (13) 5 (23) 57 (13) 0.188#
Hyperlipidemia 201 (42) 13 (59) 188 (41) 0.101
Smoking 139 (29) 9 (41) 130 (28) 0.216
Previous stroke/TIA 88 (19) 7 (32) 81 (19) 0.153
Prior use of antiplatelets 134 (28) 5 (23) 129 (28) 0.562
Prior use of statins 98 (21) 4 (18) 94 (21) 1.000#
Mean systolic blood pressure (SD), mm Hg* 154 (27) 151 (26) 154 (27) s
Mean diastolic blood pressure (SD), mm Hg* 82 (16) 81 (17) 83 (16) s
Mean glucose (SD), mmol/l 6.6 (1.9) 6.2 (1.4) 6.6 (1.9) s
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Functional outcome
The distribution of the modiﬁed Rankin Scale scores at 3 months after acute ischemic 
stroke was not signiﬁcantly different for both groups. At 3 months, 217 (46%) patients had 
a favorable outcome. Nine (41%) patients on a SSRI had a favorable outcome in comparison 
to 208 (46%) patients not on a SSRI (p = 0.65). In a multivariable analysis with adjustment 
for confounders SSRI use shows a trend to association with unfavorable functional outcome 
(OR 0.40 with 95% CI 0.14-1.13 and p = 0.08) (Table 2). In contrast, younger age, lower 
NIHSS score at presentation and lower serum glucose levels were signiﬁcantly associated 
with a favorable functional outcome. 
Of the 376 patients with a cortical stroke (of which 16 patients were on a SSRI), 147 (39%) 
had a favorable functional outcome. Three (19%) of the patients on a SSRI and 144 (40%) 
of the non SSRI users had a favorable outcome with a trend to signiﬁcance (p = 0.088). The 
ﬁnal multivariable regression model showed an association between SSRI use and 
unfavorable outcome (OR 0.17 with 95% CI 0.04-0.73 and p = 0.017) (Table2). Younger 
age and lower NIHSS score at presentation were signiﬁcantly associated with a favorable 
outcome. 
Of the 77 patients with a lacunar stroke, 5 used a SSRI. Sixty (78%) patients had a favorable 
outcome, all of the 5 patients using a SSRI (100%) and 55 (76%) of the patients naive to 
SSRI treatment (p = 0.58). A multivariable analysis was not performed because of the small 
number of SSRI users with a lacunar stroke. 
Discussion
To our knowledge, this is the ﬁrst clinical study to investigate the effect of prior SSRI use 
on functional outcome in patients with acute ischemic stroke treated with tPA. Our results 
suggest that prior SSRI use is associated with a less favorable outcome (mRS >2), especially 
in patients with a cortical stroke. In contrast to our ﬁndings, two earlier clinical studies 





Variables OR 95% CI p OR 95% CI p
SSRI therapy 0.40 0.14 – 1.13 0.083 0.17 0.04 – 0.73 0.017
Age, year 0.95 0.93 – 0.96 <0.001 0.95 0.93 – 0.96 <0.001
NIHSS score 0.81 0.77 – 0.85 <0.001 0.82 0.77 – 0.86 <0.001
Serum glucose level (mmol/L) 0.88 0.78 – 1.00 0.04527
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investigating the neuroprotective effect of ﬂuoxetine found an improved motor function 
following treatment with ﬂuoxetine.  14,15  However, treatment with ﬂuoxetine was started a 
few weeks to months after the stroke. Our patients were already treated with a SSRI before 
their stroke. 
A deleterious effect of SSRIs used prior to the stroke might be explained by enhanced 
glutamate toxicity. Long term SSRI treatment promotes BDNF transcription and increases 
the BDNF concentration. 10,11,18  However, BDNF induces glutamate release and sensitivity, 
and glutamate in turn stimulates also BDNF production, resulting in a vicious circle. 19 
Excessive sustained elevation of extracellular glutamate causes excitotoxicity, especially 
under conditions of reduced energy and oxygen availability as happens during acute 
ischemic stroke. 20,21  
Our study was performed in patients with acute ischemic stroke treated with tPA. We 
cannot exclude a possible interaction of SSRI use with tPA, because we have no control 
group of patients without tPA treatment. These could be an interesting area of further 
research, since no data exist on such possible interaction. 
A weakness of our study is the small number of patients using an SSRI. Because of the small 
sample size, no sub-analysis based on individual SSRIs could be performed. The drug 
dosage regimens were different between the patients and we did not evaluate drug 
compliance.
Our patients used SSRIs because of previous depression. We have no information on 
the severity of their depression just prior to the stroke. There is recent literature suggesting 
intracerebral neuro-inﬂammatory changes in depression.  22  However, how this may 
inﬂuence functional outcome after stroke is not clear, especially when patients are already 
treated for their depression with SSRIs.
The worldwide increase in the number of patients with depression or mood disturbances 
and the widely use of SSRIs underlie the need for taking these factors into consideration 
when evaluating therapies for acute ischemic stroke.
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Abstract
Background 
Preliminary ﬁndings suggest that statins may have a neuroprotective effect in patients with 
acute ischemic stroke. This study investigated whether patients prior on statin therapy and 
treated with tissue plasminogen activator (tPA) for acute ischemic stroke have a better 
functional outcome than statin-naïve patients. 
Methods 
In a prospective observational cohort study of 476 acute ischemic stroke patients treated 
with tPA we investigated the relationship between prior statin use and functional outcome 
at 3 months, the occurrence of symptomatic intracerebral hemorrhage (SICH) and early in-
hospital mortality. Ischemic stroke subtypes were deﬁned according to the TOAST 
classiﬁcation. Favorable outcome was deﬁned as a modiﬁed Rankin Scale score ^ 2. 
Results 
Of the 476 patients included, 98 (20.6%) used a statin at stroke presentation. In the entire 
cohort, 45.6% of patients had a favorable outcome with no difference between patients with 
or without statin therapy (45.9 vs. 45.5%, p = 0.94). In the multivariable analysis, statin use 
was not associated with favorable outcome (OR = 1.1, 95% CI = 0.6–1.9, p = 0.87). In none 
of the different stroke subtype groups was statin use associated with favorable outcome. 
Finally, statin use was not an independent risk factor of SICH or of early in-hospital 
mortality. 
Conclusion 
Prior statin therapy in patients with acute ischemic stroke treated with tPA is not associated 
with a more favorable outcome, and this is independent of stroke subtype.33
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Introduction
In the last decade, statins were widely used in the primary and secondary prevention of 
cardiovascular disease. The protective effect of statins on atherogenesis is thought to be 
caused by lowering the low-density lipoprotein (LDL) cholesterol levels. The Stroke 
Prevention by Aggressive Reduction in Cholesterol Levels Study demonstrated beneﬁcial 
effects on stroke prevention in patients with cerebrovascular disease. 1  Statins may also 
have vasoprotective and neuroprotective effects in acute ischemic stroke. 2-7  This non-
cholesterol-dependent or so-called pleiotropic effect of statins may be caused by anti-
inﬂammatory effects or effects on the nitric oxide system resulting in modiﬁcation of 
endothelial function. 8-10  The possible neuroprotective effect is probably more evident in 
non-cardio-embolic stroke, e.g. atherothrombotic and lacunar infarcts.  1,11,12 However, 
statins and lower LDL cholesterol levels have also been associated with an increased risk of 
symptomatic intracerebral hemorrhage (SICH) in patients treated with tissue plasminogen 
activator (tPA). 13  A small retrospective study found an association between prior statin use 
and a better functional outcome in patients treated with tPA in acute ischemic stroke in 
comparison to patients without statins, but this result awaits conﬁrmation. 2  The primary 
aim of this study was to investigate the effect of prior statin use on functional outcome in 
acute ischemic stroke patients treated with tPA. We also studied this possible effect in 
stroke subtypes. Finally, we assessed the effect of statin use on the occurrence of SICH and 
early in-hospital mortality.
Methods
Data of consecutive ischemic stroke patients receiving tPA were collected in a single-centre 
database from April 2002 until March 2009. Patients were treated with tPA within a time 
window of 4.5 h after onset of symptoms according to a protocol which has been described 
previously. 14  Prior medication use and doses were recorded for antiplatelet and lipid-
lowering drugs. Drug compliance was not assessed. Based on clinical and neuro-imaging 
ﬁndings, stroke subtypes were classiﬁed according to the TOAST classiﬁcation. 15 Infarction 
of undetermined origin and infarction due to other causes were taken together for analysis.
Outcome
Functional outcome at 3 months after onset of symptoms was measured using the modiﬁed 
Rankin Scale (mRS). The mRS was scored by a trained stroke nurse. Favorable outcome 
was deﬁned as a mRS score of 0–2, corresponding to independence with regard to activities 
of daily living. The occurrence of SICH was deﬁned according to the SITS-MOST criteria. 16  
Early in-hospital mortality was deﬁned as mortality within 7 days of hospital stay.
334
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Statistical analysis
Differences in baseline characteristics between patients with and without treatment with 
statins were assessed with the Mann-Whitney U test for continuous and ordinal variables 
without a normal distribution and Pearson’s X2 test and Fisher’s exact test for dichotomous 
variables. Variables within the univariate baseline characteristics for statin use or non-statin 
use with a p value < 0.20 were selected as covariates for a multivariable logistic regression 
analysis. Because of the aim of the study, statin use was also entered in the multivariable 
analysis, regardless of the univariate analysis. Since age, NIHSS score at presentation and 
glucose concentration at presentation are known variables related to outcome, these 
variables were also entered in the multivariable analysis regardless of the univariate analysis. 
In the ﬁnal logistic regression model with favorable outcome as a dependent variable, 
adjusted variables with a p value > 0.20 were removed. The analysis was furthermore 
stratiﬁed into subgroups based on infarct subtype.
All statistical analyses were performed using SPSS version 16.0. Statistical signiﬁcance 
was taken to be at a two-tailed level of < 0.05. In the multivariable analysis, a binary 
logistic regression was used with adjustment for possible confounders to calculate odds 
ratios with a 95% conﬁdence interval.
Results
Patient sample
A total of 478 patients were studied. In this group, data on functional outcome were 
missing in 2 patients and these patients were excluded. Of the 476 included patients, 98 
(20.6%) patients were using statins at stroke presentation. Baseline characteristics of statin 
users and patients not on a statin are shown in Table 1. Statin users had signiﬁcantly more 
vascular risk factors compared to non-statin users. Patients on statins also used signiﬁcantly 
more antiplatelets at stroke onset. Stroke subtype was not signiﬁcantly different between 
the two groups. Statin users had signiﬁcantly lower plasma cholesterol and LDL levels.35
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Table 1: Baseline characteristics entire cohort (n=476)
Statin user Non statin user
Characteristic N=98 N=378 p
Age (mean ± SD), years 71 ± 11 67 ± 15 0.15a
Male 53 (54) 204 (54) 0.984
NIHSS score (mean ± SD) b 12 ± 6 13 ± 6 0.502a
Time until treatment (mean ± SD), min b 153 ± 50 165 ± 50 0.028a
Stroke subtype
Atherotrombotic 34 (35) 99 (26) 0.095
Small vessel disease 10 (10) 33 (9) 0.650
Cardio-embolic 20 (20) 92 (24) 0.414
Other cause 1 (1) 18 (5) 0.143c
Unknown cause 33 (34) 136 (36) 0.671
Early ischaemic changes on brain CT scan 31 (31) 159 (42) 0.054
Hypodensity area > 33% on brain CT scan 9 (9) 20 (5) 0.151
Vascular risk factors
Hypertension 59 (60) 161 (42) 0.002
Diabetes 23 (23) 38 (10) 0.001
Hyperlipidemia 64 (65) 137 (36) <0.001
Smoking 21 (21) 118 (31) 0.058
Previous stroke/TIA 36 (36) 52 (13) <0.001
Prior use of antiplatelets 59 (60) 75 (19) <0.001
Systolic blood pressure (mean ± SD), mm Hg b 153 ± 26 154 ± 27 0.615a
Diastolic blood pressure (mean ± SD), mm Hg b 80 ± 14 83 ± 17 0.099a
Mean glucose (SD), mmol/l 6,7 ± 2,0 6,5 ± 1.9 0.222a
Total cholesterol (mean ± SD), mmol/Ld 4.1 ± 1.1 5.1 ± 1.1 <0.001a
LDL (mean ± SD), mmol/le 2.3 ± 0.9 3.4 ± 1.7 <0.001a
Values are numbers (%), unless otherwise indicated. P-values calculated with Pearson’s X2 test. 
a -ANN
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Functional outcome entire cohort
After 3 months, 217 patients (45.6%) had a favorable outcome (mRS score 2). The 
number of patients with a favorable outcome was not signiﬁcantly different between 
patients on statins and non-statin users (45.9 vs. 45.5%, p = 0.94). In the ﬁnal multivariable 
analysis, with adjustment for the confounders age, NIHSS score, hypodensity area of more 
than 33% on brain CT scan, history of hypertension, diabetes mellitus, diastolic blood 
pressure and prior use of antiplatelet drugs, statin use was not associated with a favorable 
outcome (OR = 1.1, 95% CI = 0.6–2.0, p = 0.73; Table 2).
Table 2: Final logistic regression model with predictors of favorable outcome
Entire cohort (n=476)
Variables OR 95% CI p
Statin therapy 1.11 0.61 – 2.01 0.73
Age, year 0.95 0.93 - 0.96 <0.001
NIHSS score 0.82 0.78 - 0.86 <0.001
Hypodensity area > 1/3 on brain CT scan 0.23 0.07 – 0.71 0.01
Hypertension 0.65 0.41 – 1.05 0.08
Diabetes Mellitus 0.53 0.26 – 1.05 0.07
Prior antiplatelet therapy 1.65 0.96 – 2.85 0.07
Diastolic blood pressure, mm Hg 1.01 1.00 – 1.03 0.08
Stroke subtype
The distribution of stroke subtype according to the TOAST classiﬁcation and statin use is 
shown in Table 1. Favorable outcome was not signiﬁcantly different between statin users 
and patients not on statins in all subgroups according to the TOAST classiﬁcation. 
Especially, for patients with atherothrombotic stroke a signiﬁcant difference in functional 
outcome between statin use and non-use was not found (56 vs. 41%, p = 0.144; Table 3). 
After correction for possible confounders, prior statin use was still not associated with 
favorable outcome.
Table 3: Favorable outcome for stroke subtype
Stroke etiology Statin use Non statin use p
Atherotrombotic 19/34 (56) 41/99 (41) 0.14
Small vessel disease/Lacunar stroke 10/10 (100) 27/33 (82) 0.31a
Cardio-embolic 6/20 (30) 39/92 (42) 0.31
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Early in-hospital mortality and occurrence of SICH
There was no difference in early in-hospital mortality between patients with statin use and 
without statin use (9 vs. 9%, p = 0.82). In the entire cohort, SICH was more often seen in 
patients using statins compared to patients not using statins (10 vs. 5%, p = 0.041). 
However, in the multivariable analysis, statin use was not independently associated with 
the occurrence of SICH (OR = 1.6, 95% CI = 0.57–4.37, p =0.38). Higher serum glucose 
levels, antiplatelet therapy, higher NIHSS score at presentation and a hypodensity area of 
more than 33% on brain CT scan were independent predictors of SICH.
Discussion
This study could not demonstrate that patients with prior statin use and treated with tPA 
for acute ischemic stroke had a better functional outcome at 3 months in the entire cohort 
and in the different subgroups based on stroke subtype. Moreover, statin use did not reduce 
early in-hospital mortality or increase the occurrence of SICH. Our study could not conﬁrm 
the results of a previous similar observational study investigating this topic. 2  In this study, 
145 patients treated with tPA were analyzed and prior statin use was an independent factor 
for good functional outcome after 3 months with an odds ratio of 5.3 (95% CI = 1.5–18.7, 
p = 0.027). This study used the same deﬁnition of favorable outcome (mRS score 2). An 
explanation for the discrepancies between the previous and our study may be differences 
in baseline characteristics of the two cohorts. Stroke severity was signiﬁcantly higher in the 
study of Alvarez-Sabin et al. 2 , while in our study there were more patients with a history 
of transient ischemic attack/stroke and less patients with a potential cardio-embolic stroke. 
These imbalances may have led to the difference in results. Another difference is the sample 
size of the two studies. The sample size of the study by Alvarez-Sabin et al. 2  was relative 
small and 95% conﬁdence intervals were wide. Our sample size was about three times 
larger with substantially smaller conﬁdence intervals and therefore the results of our study 
may be more reliable.
Early in-hospital mortality in our study did not differ between the two groups, which 
indicates that there is no short-term beneﬁcial effect of statins, as suggested in a study by 
Marti-Fabregas et al.. 5  In the univariate analysis, statin use was associated with increased 
risk of SICH, but in multivariable analysis this lost signiﬁcance. Therefore, statin use is not 
an independent risk factor for SICH, which was also observed in other studies. 13,17  A 
previous study using astrocytes from rats suggested that statins may reduce the risk of 
SICH by down-regulating matrix metalloproteinase-9 activity. Up-regulation of matrix 
metalloproteinase-9 is stimulated by tPA and mediates a breakdown of the blood-brain 
barrier causing hemorrhagic transformation. 18  A possible protective effect of statins on 
tPA-related hemorrhagic complications needs further investigation in clinical studies. 
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Our study has limitations. First, this is an observational study with a relatively small 
number of patients, especially with regard to the subgroups and this limits statistical 
analysis. Second, in comparison to other studies, a large amount of patients in our study 
were classiﬁed as having ‘unknown’ stroke etiology according to the TOAST classiﬁcation. 
Our hospital has a regional function in the treatment of stroke patients with tPA. After tPA 
treatment, some patients were transferred to hospitals in the region. Therefore, we did not 
have access to all the diagnostic ﬁndings of these patients, except for the functional outcome 
at 3 months. Third, all statins were considered together, although they may not share all 
effects. 19  We did not perform any sub-analysis based on individual drugs. However, the 
results mainly reﬂect the effect of simvastatin and atorvastatin used by 45.9 and 42.9% of 
the patients, respectively. Furthermore, we did not assess drug compliance. However, 
cholesterol and LDL plasma levels were signiﬁcantly lower in statin users than in non-
users, suggesting that there was sufﬁcient compliance in the statin user group. Although 
cholesterol and LDL levels were low, in experimental studies ﬁnding a neuroprotective 
effect of statins, high dosages of statins were needed to achieve neuroprotection with 
consequently very low LDL plasma levels, which might not be the case in our study. 20 
There was no withdrawal of statins in the acute phase of stroke or after hospitalization, 
which could explain the results. 21 
In conclusion, our study does not support the hypothesis that prior statin therapy in 
patients with acute ischemic stroke treated with tPA is associated with a more favorable 
outcome, independent of stroke subtype. Therefore, we question whether statins have a 
neuroprotective effect in acute ischemic stroke.39
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Abstract
Background 
The prognostic value of serum uric acid (UA) in acute ischemic stroke is controversial. The 
aim of this study is to further analyze the relation between UA and outcome after acute 
ischemic stroke. 
Methods 
We analyzed UA levels in blood samples collected within 6 hours of stroke onset from 
patients included in the placebo arm of the US and Canadian Lubeluzole Ischemic Stroke 
Study (LUB-INT-9). We compared mean serum UA levels in patients with and without 
early neurological improvement ( 4 versus < 4 points improvement on NIHSS after 5 
days) and in patients with good functional and poor functional outcome (mRS 0-2 versus 
mRS 3-6). Multivariable logistic regression analyses were performed to adjust for possible 
confounders.
Results 
UA levels of 226 patients were available for analysis. Mean serum UA levels were not 
signiﬁcantly higher in patients with than without early neurological improvement (0.33 
mmol/L versus 0.30 mmol/L, p = 0.070). The difference between patients with good and 
patients with poor functional outcome was borderline statistically signiﬁcant (0.34 mmol/L 
versus 0.31 mmol/L, p = 0.050). After adjustment for confounders, higher serum UA levels 
were neither associated with early neurological improvement OR (1.30, 95% CI 0.98-1.73, 
p = 0.069), nor with a good functional outcome (OR 1.09, 95% CI 0.72-1.65, p = 0.690). 
Conclusion 
We found no association between admission serum UA levels and both short- and long-
term outcome in acute ischemic stroke.  43
Lack of association between serum uric acid levels and outcome in acute ischemic stroke
Introduction
Uric acid (UA) is a predictor for developing cardiovascular disease and stroke by 
mechanisms involved in development and progression of atherosclerosis, but it remains 
controversial whether this is an independent effect of uric acid by itself or an epiphenomenon. 
It is also thought that the effect is linked to other factors that predispose cardiovascular 
disease and stroke, like hypertension and diabetes, which are associated with uric acid. 1,2  
On the other hand, UA is a powerful anti-oxidant contributing to approximately two third 
of free radical scavenging in plasma. 3,4  
Oxidative stress in the acute phase of ischemic stroke increases brain injury. 3,5  Oxidative 
stress reﬂects an imbalance between potentially harmful oxidants and protective 
antioxidants and predisposes to local tissue damage, partly through excess free radical 
activity. In this perspective UA could act as a free radical scavenger reducing oxidative 
stress in patients with acute ischemic stroke and protect cells in the ischemic penumbra. In 
addition, an interventional study showed that administration of uric acid in healthy 
volunteers with low baseline serum concentrations increased the antioxidant capacity. 6 
Therefore, UA might be neuroprotective in acute ischemic stroke. 
A neuroprotective effect of UA has been shown in animal studies of focal brain ischemia. 
7,8   However the prognostic value of serum uric acid in acute ischemic stroke in human 
remains controversial. Chamorro et al. found an inverse correlation between serum UA 
concentrations and early neurological improvement and ﬁnal infarct size. 9  Two recent 
studies found that higher serum UA levels were independently associated with good 
functional outcome and smaller infarct volumes in patients treated with thrombolysis. 10,11    
There are also reports of a detrimental effect of serum UA concentration on functional 
outcome. 12-16  For example, a large study by Weir et al. showed that increase in admission 
serum UA levels independently predicted worse outcome. 16  Although the exact mechanisms 
of this detrimental effect are still unknown, increased UA concentration may be associated 
with platelet adhesiveness with inﬂuence on thrombus formation or could become a pro-
oxidant under certain circumstances. 5,17 
The aim of this study is to further analyze the relation between serum UA levels and 
outcome after acute ischemic stroke. We assessed the relation between UA and early 
neurological improvement at day 5 after stroke and with functional outcome at 3 months 
after stroke. 
Methods
Data were obtained from the United States and Canadian Lubeluzole in Ischemic Stroke 
Study (LUB-INT-9), a multicenter, randomized, placebo controlled-trial investigating the 
efﬁcacy and safety of lubeluzole in acute ischemic stroke patients. 18  Only data from the 
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placebo treated patients were used. Blood samples were collected within 6 hours of stroke 
onset and serum UA concentration was measured in mmol/L. Neurological status was 
examined by using the National Institute of Health Stroke Scale (NIHSS) and modiﬁed 
Rankin Scale (mRS). Classiﬁcation of ischemic stroke subtypes was based on the TOAST-
criteria and included small vessel disease, large vessel disease and cardio-embolic strokes 19  
Outcome
Early neurological improvement and functional outcome at 3 months after acute ischemic 
stroke were used as outcome measures. We deﬁned early neurological improvement as  4 
points improvement in score of NIHSS after 5 days of the initial event. Functional outcome 
was deﬁned according to the modiﬁed Rankin Scale (mRS) and dichotomized into favorable 
outcome (mRS 0-2), corresponding to independence with regard to activities of daily 
living, and unfavorable outcome (mRS 3-6). To compare with previous studies, the relation 
with excellent outcome (mRS 0-1) was also assessed. 
Statistics
Baseline characteristics for the entire cohort were calculated. Mann Whitney U-test was 
used for continuous and ordinal variables without a normal distribution. Pearson’s Chi 
Square test was used for dichotomous variables. Variables within univariate analysis for 
serum UA levels < and  0.32 mmol/L (mean) with a p-value < 0.20 were selected as 
covariates for the multivariable logistic regression analysis. Regardless of the difference in 
baseline characteristics, age, NIHSS score and serum glucose level at presentation were 
entered in the multivariable analyses. 
These variables were considered to be possible confounders, since these variables are 
related to outcome in patients with acute ischemic stroke. (20) Furthermore because of the 
association between UA and cardiovascular risk factors, a history of hypertension, coronary 
artery disease and previous stroke were also entered as covariates in the multivariable 
analysis. 1  In the multivariable analysis with early neurological improvement or favorable 
outcome as dependent factor, variables with a p value > 0.20 were removed from the 
model. 
All statistical analyses were performed using PASW Statistics version 18.0. Statistical 
signiﬁcance was taken to be at two tailed level < 0.05. A binary logistic regression model 
was used for multivariable analysis, with adjustment for possible confounders, to calculate 
odds ratios with 95% conﬁdence interval. 
Results
Patient sample
Out of the 353 patients in the placebo group of the LUB-INT-9 trial, only 233 patients were 
included because of availability of serum UA levels in these patients. 45
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Another 7 patients were excluded because of lack of data on functional outcome at 3 
months. Therefore, baseline characteristics were calculated for 226 patients (64% of total 
population) and are presented in Table 1. Mean age of the cohort was 71 years (SD 12) 
with a slightly higher number of men than women (54 vs 46%). Mean serum UA level was 
0.32 mmol/L (SD 0.10). Median NIHSS at presentation was 15 (IQR 11-19) and median 
NIHSS at day 5 was 12 (IQR 6-18). Almost two third of patients were diagnosed with 
hypertension (62%). 75 patients (33%) had a cardio-embolic stroke and 57 patients (25%) 
were diagnosed with large vessel disease stroke. 
Eighty-seven patients (38%) showed early neurological improvement (improvement of 
NIHSS  4 points at day 5); 47 patients (21%) had a favorable outcome and 42 patients 
(19%) had an excellent outcome at 3 months (Table 2). A number of 120 patients were 
excluded because of no availability of serum UA levels. Of these 120 patients 7 had a 
hemorrhagic stroke and 5 had no data on functional outcome at 3 months available. The 
other 108 patients did not differ signiﬁcantly in baseline characteristics from the included 
patients. 
Table 1: Baseline characteristics 
Included population  Excluded population
Characteristic (n = 226) (n = 108) p
Male (%) 123 (54%) 61 (57%) 0.72
Mean age (SD), year 71 (12) 69 (13) 0.20b
Median NIHSS at presentation (IQR) 15 (11-19) 13 (10-19) 0.10b
Mean serum glucose level (SD), mmol/La  8.0  (3.4) 7.9 (3.7) 0.33b
Mean diastolic RR (SD), mm Hg  84 (16) 82 (17) 0.36b
Mean serum uric acid level (SD), mmol/L  0.32 (0.10) n.a.
Vascular risk factors
Hypertension (%) 140 (62%) 66 (61%) 0.88
Diabetes (%) 46 (20%) 28 (26%) 0.25
Atrial ﬁbrillation (%) 58 (26%) 27 (25%) 0.90
Coronary artery disease (%) 74 (33%) 30 (28%) 0.36
Smoking (%) 57 (25%) 23 (21%) 0.43
Stroke subtype
Cardio-embolic (%) 75 (33%) 36 (33%) 0.98
Large vessel disease (%) 57 (25%) 21 (20%) 0.24
Small vessel disease (%) 32 (14%) 12 (11%) 0.44
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Table 2: Outcome variables
 
Total population 
Outcome (n = 226)
Early neurological improvement (%)  87 (38%)a
Median NIHSS after 5 days (IQR) 12 (6-18)a
MRS 0-2 at 3 months 47 (21%)
MRS 0-1 at 3 months 42 (19%)
 
Values are number unless otherwise indicated. 
)12 INTER
QUARTILE RATIO a  MISSING 
Early neurological improvement 
Mean serum UA concentration was not signiﬁcantly higher in patients with than without 
early neurological improvement. (0.33 mmol/L versus 0.30 mmol/L, p = 0.070; Figure 1). 
In the univariate analysis, serum UA level was signiﬁcantly associated with early 
neurological improvement (OR 1.35, 95% CI 1.02-1.79, p = 0.036). However, signiﬁcance 
was lost after adjustment for confounders (OR 1.30, 95% CI 0.98-1.73, p = 0.069; Table 3). 
In the ﬁnal logistic regression model, male gender was associated with early neurological 
improvement (OR 1.77, 95% CI 1.00-3.12, p = 0.048). 
Table 3: Multivariable analysis: association of UA and early neurological improvement
Early neurological improvement
Variables OR 95% CI p
Serum uric acid level, mmol/L (per 0.1 mmol/L) 1.30 0.98 – 1.73 0.069
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Functional outcome
A near signiﬁcant difference was found in serum UA level between patients with favorable 
and patients with poor functional outcome (0.34 mmol/L versus 0.31 mmol/L, p = 0.050) 
(Figure 1).  Regarding excellent functional outcome, serum UA level was signiﬁcantly 
higher in patients with than in patients without excellent functional outcome (0.33 mmol/L 
versus 0.31 mmol/L, p = 0.032).
After adjustment for confounders serum UA level was no longer associated with a 
favorable outcome (OR 1.16, 95% CI 0.86-1.56, p = 0.356) or excellent outcome (OR 
1.09, 95% CI 0.72-1.65, p = 0.690). In the ﬁnal multivariate analysis lower age, lower 
baseline NIHSS, lower serum glucose levels, no previous history of diabetes and no large 
vessel stroke were associated with a favorable or excellent outcome (Table 4). 
Table 4: Multivariable analysis: association of UA and favorable outcome
Favorable outcome Excellent outcome
Variables OR 95% CI p OR 95% CI p
Serum uric acid level, mmol/L 
(per 0.1 mmol/L) 1.09 0.72 – 1.65 0.690 1.14 0.74 – 1.78 0.552
Age, year 0.95 0.92 – 0.98 0.002 0.98 0.92 – 0.98 0.002
NIHSS score 0.84 0.77 – 0.91 <0.001 0.78 0.77 – 0.91 <0.001
Serum glucose level 0.83 0.68 – 1.00 0.049 0.86 0.69 – 1.01 0.070
History of diabetes 0.20 0.04 – 0.97 0.046 0.20 0.04 – 0.94 0.042






We found no association between serum UA levels and early neurological improvement at 
day 5 or favorable functional outcome at 3 months after the initial ischemic stroke. 
In the literature, different ﬁndings for and against a neuroprotective effect of UA were 
found as is summarized in Table 5. A study by Chamorro et al. found a 12% increase of the 
odds of good outcome at hospital discharge (mean 11 days after admittance) for each 
milligram per deciliter increase of serum UA. 9  In a recent study by Amaro et al. in patients 
with ischemic stroke also treated with reperfusion therapies, increased serum UA levels 
were independently associated with a mRS score of 0-1 at 3 months after the initial event. 
10  In contrast, another study by Dawson et al. could not ﬁnd an independent association of 
UA levels with functional outcome at 3 months. 12  Karagiannis et al. reported that elevated 
levels of UA are independently associated with early death after ischemic stroke (median 4 
days after stroke, IQR 2-7). 13  Newman et al. found that elevated UA concentration is 
448
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independently associated with increased risk of future vascular events in patients with 
diabetes mellitus type 2. 14  Seet et al. found that both patients with relatively decreased and 
with elevated serum UA levels had poor functional outcome compared to patients with 
median serum UA levels one year after the initial event. 15  Weir et al showed that increased 
serum UA levels independently predicted worse outcome 3 months after stroke (alive in 
care or death). 16  Logallo et al found a beneﬁcial effect of UA in patients treated with tPA, 
but they could not extend this to non-treated patients. 11  The difference in ﬁndings as 
described above is additionally complicated by the use of different outcome measures and 
also study size and population, consequently hamper comparing of the various results. 
Also timing of UA sampling is different between all studies, which could also be of inﬂuence 
on the results. 
Looking at our study in comparison with the previous ones, we found also no neuroprotective 
effect of serum UA levels, neither in the early phase after the ischemic stroke nor in the late 
phase. A possible explanation for the protective effect of UA in the acute phase of ischemic 
stroke is thought to be explained by reducing oxidative stress in the ischemic penumbra 
and thereby reducing the deﬁnite infarct volume as has been found in earlier both animal 
and human studies. 8,10,21  We can not conﬁrm this hypothesis with the results of our study. 
An explanation could be that the neuroprotective effect of serum UA is too small to result 
in signiﬁcant difference in the larger outcome scales. However, even when we look at 
improvement of NIHSS at day 5 after the initial stroke, a more speciﬁc marker than the 
larger mRS score, no neuroprotective effect of serum UA was found. As mentioned, we also 
could not extend this effect to the outcome at 3 months. This is in contrast with the study 
by Amaro et al. 10  Also when we adjust our analysis to the same outcome measure (excellent 
outcome, mRS 0-1 at 3 months) serum UA level was not associated with excellent outcome 
(Table 3). An explanation for the difference in results for outcome at 3 months could be the 
more severe strokes in our cohort showed by higher baseline NIHSS and fewer patients 
with favorable outcome. In our cohort the median baseline NIHSS was 15 (IQR 11-19) and 
47 patients (21%) with a mRS of 0-2 versus a median baseline NIHSS of 11 (IQR 6-18) and 
153 patients (48%) with a mRS of 0-2 in their cohort. Amaro et al. used as outcome 
measure mRS of 0-1. In addition, the study by Amaro et al. was performed using patients 
also treated with alteplase. Animal studies have demonstrated a synergic neuroprotective 
effect in rats treated with alteplase and administration of UA. 7  Thus their ﬁnding of an 
association of serum UA levels and excellent outcome could also be inﬂuenced by the 
synergic effect of alteplase. This could also explain why Logallo et al found a neuroprotective 
effect in the alteplase treated patients and not in the larger cohort of non-treated patients. 
21  At the moment, the URICO-ICTUS study is trying to evaluate the clinical efﬁcacy of UA 
administration in acute ischemic stroke patients treated with alteplase within the 4,5 hour 
time window in a phase 3 randomized double-blind controlled trial. 22  
Another hypothesis could be that the neuroprotective effect in the acute phase of the 
initial stroke is counteracted by the expression of also more cardiovascular disease in these 
patients with higher serum UA levels, with also impact on the outcome scores.  
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Our study was limited by the lack of serial UA level measurements. We determined the 
baseline UA levels, therefore we could not assess whether UA levels decreased or increased 
in patients with early neurological improvement or good functional outcome. Furthermore, 
we could not adjust for serum creatinine levels or renal insufﬁciency, which both could be 
possible confounding factors by their association with elevated UA levels and inﬂuence on 
outcome. In addition, we did not adjust for the use of diuretics, which also could inﬂuence 
serum UA levels.  No data of infarct size after the initial stroke were available and thus we 
could not compare infarct size with serum UA levels. It would be interesting to further 
investigate this subject for instance with size of perfusion/diffusion weighted MRI-lesions 
in relation to serum UA levels. Finally, our sample size was relative small compared to 
previous studies on this subject. Although our study could not identify an association 
between serum UA levels and short/long term outcome, a small positive effect could be 
missed due to the small sample size.
In conclusion, serum UA levels were not associated with early neurological improvement 
at day 5 and favorable functional outcome at 3 months after the initial ischemic stroke. Our 
results do not support the neuroprotective hypothesis of serum UA. 51
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Abstract
Background 
The prognostic inﬂuence of hyperglycemia in acute ischemic stroke has been well 
established. While in cortical stroke there is a strong association between hyperglycemia 
and poor outcome, this relation is less clear in lacunar stroke. It is unclear if this discrepancy 
is present among patients treated with intravenous tissue plasminogen activator (tPA). 
Methods 
In two prospectively collected cohorts of patients treated with intravenous tPA for acute 
ischemic stroke, we investigated the effect of hyperglycemia (serum glucose level >8 
mmol/L) on functional outcome and occurrence of symptomatic intracranial hemorrhage 
(SICH) in lacunar and non-lacunar stroke. Poor functional outcome was deﬁned as 
modiﬁed Rankin Scale score 3-6 at 3 months. 
Results 
Of the 857 patients included, 161 patients (19%) had lacunar stroke and 696 (81%) non-
lacunar stroke. The prevalence of hyperglycemia did not differ between stroke subtypes 
(21% versus 19%, p = 0.58). In multivariate analysis hyperglycemia was associated with 
poor outcome in lacunar strokes (OR, 2.61; 95% CI, 0.98-6.02; p = 0.056) and signiﬁcantly 
associated with poor outcome in non-lacunar strokes (OR, 1.59; 95% CI, 1.03-2.57;   
p = 0.033). The incidence of SICH was not different between hyperglycemic and normo-
glycemic patients in either stroke subtype. 
Conclusion 
In acute ischemic stroke patients treated with intravenous tPA, hyperglycemia is an 
independent predictor of poor functional outcome in both patients with non-lacunar 
stroke and lacunar stroke.55
Introduction
Admission hyperglycemia is common in patients with acute ischemic stroke and occurs 
among all stroke subtypes. 1  Hyperglycemia is independently associated with poor 
functional outcome in patients with acute ischemic stroke. In patients treated with 
intravenous recombinant tissue plasminogen antigen (tPA), hyperglycemia was associated 
with lower recanalization rates and was a strong predictor of symptomatic intracerebral 
hemorrhage (SICH), regardless of a history of diabetes. 2-9  In addition, admission 
hyperglycemia was independently associated with mortality. 2,6,9  
While in cortical stroke there is a strong association between hyperglycemia and poor 
outcome, this relation is less clear in lacunar stroke. Two previous studies even report a 
favorable effect of moderate hyperglycemia in lacunar stroke. 4,8  It is unclear if this 
discrepancy is present among patients treated with intravenous tissue plasminogen 
activator (tPA). We aimed to investigate the effect of admission hyperglycemia on functional 
outcome and the risk of symptomatic intracranial hemorrhage (SICH) in patients with 
lacunar and non-lacunar strokes treated with intravenous tPA. 
Methods
Data were obtained from two stroke centers in the Netherlands and Belgium. Both centers 
have an ongoing prospective registry of consecutive patients with acute ischemic stroke 
treated with intravenous tPA treatment. The registry was started at the University Medical 
Centre of Groningen (UMCG) in April 2002. All patients registered between April 2002 
and October 2012 were included in this study. In the Universitair Ziekenhuis Brussel 
(UZB), the registry was started in March 2009. In both hospitals tPA treatment was 
performed within a time window of 4.5 hours after onset of symptoms according to a 
protocol which has been described earlier. 10 
Stroke severity before administration of tPA was assessed according to the National Institute 
of Health Stroke Scale (NIHSS). Stroke subtype was classiﬁed as lacunar stroke (LACI = 
lacunar infarct) or non-lacunar stroke (PACI = partial anterior circulation infarct and TACI 
=  total anterior circulation infarct) according to the Oxfordshire Community Stroke Project 
Classiﬁcation. 11  Patients with posterior circulation infarction (POCI = posterior circulation 
infarct) were excluded. 
Demographic and clinical information was recorded, including cardiovascular risk factors 
and serum glucose concentration. Hyperglycemia was deﬁned as >8 mmol/L ( 144 mg/dl) 
in accordance with previous studies on this subject. 3,8,9 
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Outcome 
The modiﬁed Rankin Scale (mRS) was used to determine functional outcome at 3 months 
after stroke onset. Functional outcome was dichotomized into poor outcome meaning 
dependence or death (mRS 3-6) and favorable outcome (mRS 0-2), corresponding to 
independence with regard to activities of daily living.
The occurrence of symptomatic intracranial hemorrhage (SICH) was deﬁned according 
to the Safe Implementation of Treatment in Stroke (SITS) criteria deﬁned as a neurological 
deterioration (NIHSS  4 points) within 36 hours following tPA treatment with a paren-
chymal hematoma on brain CT-scan compatible with clinical symptoms. 12 
Statistics
Baseline characteristics for patients stratiﬁed by stroke subtype were compared. Mann 
Whitney U-test was used for continuous and ordinal variables without a normal distribution. 
Pearson’s Chi Square test and Fisher’s exact test were used for dichotomous variables. A 
binary logistic regression model is used for multivariable analysis, with adjustment for 
possible confounders, to calculate odds ratios with 95% conﬁdence interval. A history of 
diabetes is entered in the multivariable analysis and an interaction between hyperglycemia 
and a history of diabetes was tested. All statistical analyses were performed using IBM SPSS 
Statistics 20. Statistical signiﬁcance is taken to be at two tailed level < 0.05. 
Results
Patient sample
Nine hundred and ninety patients were treated with tPA during the study period. From this 
group 876 patients (88%) were treated in the UMCG and 114 patients (12%) in the UZB. 
Three month mRS scores of 53 patients were missing (5% of total population). Furthermore, 
9 patients were excluded because of missing data on stroke subtype and 71 patients (7%) 
with POCI were excluded.
We included a total of 857 patients consisting of 161 patients (19%) with lacunar 
stroke and 696 patients (81%) with non-lacunar stroke. In the non-lacunar stroke group, 
449 patients (65%) had PACI and 247 patients (35%) TACI. 
The baseline characteristics are presented in Table 1. No difference in baseline serum 
glucose levels were found between the two stroke subtypes (6.8 mmol/L versus 6.7 mmol/L, 
p = 0.58) and the occurrence of admission hyperglycemia, did not differ between the 
subtypes (21% versus 19%, p = 0.58). 57
Table 1: Baseline characteristics of the study cohort of 857 patients with acute ischemic stroke receiving intravenous tPA treatment
Lacunar stroke Non-lacunar stroke
Characteristic N=161 N=696 p-value
Male (%) 88 (55%) 363 (52%) 0.57
Mean age (SD), years 66 (15) 70 (14) 0.001e
Median NIHSS at presentation (IQR)a 6 (5-9) 13 (8-17) <0.001e
Mean systolic RR (SD), mmHgb 161 (24) 153 (29) <0.001e
Mean diastolic RR (SD), mmHgb  85 (15) 81 (18) 0.001e
Mean serum glucose level (SD), mmol/L 6.8 (1.9) 6.7 (2.2) 0.58e
Hyperglycemia (>8mmol/L) 33 (21%) 129 (19%) 0.58
Vascular risk factors
Hypertension (%) 77 (52%) 351 (50%) 0.55
Diabetes (%) 30 (19%) 103 (15%) 0.23
Hypercholesterolemia (%) 105 (65%) 389 (56%) 0.031
Atrial ﬁbrillation (%) 15 (9%) 158 (23%) <0.001
Smoking (%)c 58 (37%) 168 (25%) 0.003
History of previous stroke (%)d 35 (23%) 124 (20%) 0.42
Use of antiplatelet drugs (%)d 53 (35%) 217 (35%) 0.96
Outcome
mRS 3-6 at 3 months 36 (22%) 390 (56%) <0.001









In total, 426 patients (50%) had a poor outcome (mRS 3-6). The occurrence of poor 
outcome was signiﬁcantly different between patients with lacunar and non-lacunar strokes 
(22% versus 56%, p = <0.001). 
Univariate analysis showed that patients with lacunar stroke and normoglycemia had less 
frequently poor outcome than those with hyperglycemia (19% vs. 36%, respectively;   
p = 0.030) (Figure 1). After adjustment for possible confounders in multivariate analysis, 
admission hyperglycemia was near to a signiﬁcant association with poor functional outcome 
(OR, 2.61; 95% CI, 0.98-6.02; p = 0.056).
In non-lacunar stroke, univariate analysis also showed a signiﬁcant difference between 
normoglycemic and hyperglycemic patients with regard to poor outcome (54% vs. 67%; p 
= 0.007) (Figure 1). The association between admission hyperglycemia and poor outcome 
was conﬁrmed in multivariate analysis taking possible confounders into account (OR, 
1.59; 95% CI, 1.03-2.57; p = 0.033). Older age and higher baseline NIHSS score were 
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associated with poor functional outcome in both stroke subtypes. Testing for the interaction 
term including hyperglycemia and diabetes did not change the results in the multivariate 
models. 
Symptomatic intracranial hemorrhage
Forty-three patients (5%) suffered from SICH. The incidence of SICH was signiﬁcantly 
lower in lacunar stroke than in non-lacunar stroke (1.9% vs. 5.7%; p = 0.042). 
In lacunar stroke, univariate analysis revealed no difference in occurrence of SICH 
between normoglycemic and hyperglycemic patients (2% versus 3%, p = 0.50) (Figure 1). 
Because of the low occurrence of SICH in lacunar stroke patients, multivariate analysis 
could not be performed. Univariate analysis in non-lacunar stroke patients showed a non-
signiﬁcant higher incidence of SICH in patients with hyperglycemia compared to patients 
with normoglycemia (8% versus 5%, p = 0.28) (Figure 1). 59
Discussion
In both lacunar and non-lacunar stroke, admission hyperglycemia was associated with 
poor functional outcome after intravenous tPA treatment. In patients with non-lacunar 
stroke, hyperglycemia predicted poor functional outcome, independently of other 
predictors for unfavorable outcome. A similar effect was observed in patients with a lacunar 
stroke, though less pronounced. The incidence of SICH was not signiﬁcantly different 
between hyperglycemic and normoglycemic patients in either stroke subtype. 
The mechanisms by which hyperglycemia augments ischemic brain injury are not fully 
understood and several mechanisms are proposed: induction of acidosis by anaerobic 
glycolysis enhancing free radical production in the ischemic penumbra; increase of blood-
brain barrier permeability; increase of coagulation processes and decreased ﬁbrinolytic 
activity; and induction of vascular changes with a pro-vasoconstrictive, pro-thrombotic 
and pro-inﬂammatory effects which compromise the collateral circulation and enhance 
reperfusion injury. 13,14 
Our ﬁndings differ from two previous studies in patients not treated with thrombolytic 
therapy, showing a differential effect of hyperglycemia with regard to the ischemic stroke 
subtype. 4,8  It was suggested that the favorable functional outcome in patients with lacunar 
stroke and moderate hyperglycemia can be related to the absence of an ischemic penumbra 
in most lacunar strokes, as hyperglycemia-related mechanisms are thought to be harmful 
to the salvage of the penumbra. 5  A correlation was found between lactate levels in the 
cerebrospinal ﬂuid and functional outcome in patients with non-lacunar stroke, but not in 
patients with lacunar stroke. 15  Increased lactate production in the hyperglycemic state may 
fuel astrocytes and thus facilitate axonal survival in the white matter in lacunar stroke. (8) 
We hypothesize that lacunar stroke patients receiving thrombolytic therapy are exposed to 
aggravated reperfusion injury, which can counterbalance the protective effects of hyper-
glycemia in these patients. Therefore, hyperglycemia may exacerbate reperfusion injury 
through enhanced oxidative stress and  a stronger inﬂammatory response. 13 Moreover, 
exposure of reperfused tissue to tPA may amplify neuronal damage as neurotoxic effects of 
tPA have been shown in animal models. 16  Taken together, these mechanisms may lead to 
increased infarct size and poor functional outcome in lacunar stroke, especially in case of 
reperfusion after tPA.
Trials investigating the effects of glucose lowering in acute ischemic stroke show mostly 
disappointing results. Overall, no improvement of functional outcome was found 17 , but 
large trials on this subject are ongoing. Based on the results of our study, it may not be 
necessary to differentiate the management of hyperglycemia between stroke subtypes.
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In line with previous studies, a trend toward a higher incidence of SICH was observed 
among patients with non-lacunar stroke and admission hyperglycemia. 2,6  This effect was 
not observed in the lacunar stroke patients, but this can be explained by the very low 
absolute number of SICH in this stroke subtype. 
Our study has several limitations. Despite the quite large sample size, the subgroup of 
patients with lacunar stroke is relatively small, which may negatively inﬂuence the statistical 
power of our ﬁndings. Further, information on serial glucose measurements or glycosylated 
hemoglobin concentrations was not available. Finally, the relation between hyperglycemia 
and infarct growth was not studied by follow-up imaging. 
In conclusion, we found admission hyperglycemia to be an independent predictor of poor 
functional outcome in patients with acute ischemic stroke treated with intravenous tPA. 
Contrary to patients not receiving thrombolytic therapy, the negative effect of hyperglycemia 
on outcome was present in both non-lacunar and lacunar stroke, although less pronounced 
in the latter.61
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Prior anticoagulant therapy, subtherapeutic international 
normalized ratio and thrombolytic therapy in acute ischemic 
stroke
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Content
Due to the increased risk of symptomatic intracerebral hemorrhage (sICH) among patients 
using vitamin-K antagonist (VKA) prior to stroke, an international normalized ratio (INR) 
of >1.7 is considered as a contraindication for treatment with intravenous recombinant 
tissue plasminogen antigen (tPA). 1  However, few studies have investigated the relation 
between INR levels and sICH after tPA and the results of these are conﬂicting. 2-4  One study 
showed a higher incidence of sICH among VKA users with an INR of less than 1.7 treated 
with intravenous tPA. 4  A cohort of intra-arterial tPA treatment and another series of both 
intravenous and intra-arterial tPA treatment, found no increased risk in patients using 
VKA. 2,3  We studied the relationship between VKA use, elevated INR and outcome after tPA 
treatment.
In a prospective observational study of 524 ischemic stroke patients treated with tPA, we 
investigated the relationship between prior VKA- use, an elevated (INR), sICH and favorable 
outcome after 3 months, deﬁned as a modiﬁed Rankin scale score (mRS) 0-2. Data were 
analyzed separately for VKA users and non-VKA users and for normal INR (1.1) and 
elevated INR (1.2 – 1.7).
Of the 524 patients, 22 (4%) used VKA. An elevated INR was present in 59 (11%) patients. 
No differences were found between VKA users and non-VKA users in occurrence of sICH 
(9% vs. 6%, p=0.36) and favorable outcome (41% vs. 48%, p=0.50). Elevated INR was 
non-signiﬁcantly associated with sICH (12% vs. 5%, p=0.09) but signiﬁcantly associated 
with less favorable outcome (50% vs. 35%, p=0.03). Multivariable analyses demonstrated 
that elevated INR was associated with worse outcome and an increased risk of sICH. VKA 
treatment alone (with or without elevated INR) was only associated with increased risk of 
sICH (Table 1). 
Table 1: OR of multivariable analysis
OR for sICH and favorable outcome (mRS 0-2)
sICH and VKA use* Favorable outcome and VKA use**
OR 95% CI P  OR 95% CI P 
VKA use 5.72 1.06 – 30.75 0.042 0.86 0.28 – 2.71 0.80
sICH and INR  1.2* Favorable outcome and INR  1.2**
OR 95% CI P  OR 95% CI P 
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Our study suggests that prior VKA use with a normal or elevated INR before intravenous 
tPA was independently associated with an increased risk of sICH, but not with a poor 
functional outcome. To summarize caution should be taken to treat patients, who have an 
elevated INR, spontaneously or due to VKA, with tPA. 
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PART 2
Thrombolytic therapy for ischemic stroke in patients using 
warfarin: as systematic review and meta-analysis
I. Miedema, G.J. Luijckx, J. De Keyser, M.W. Koch, M. Uyttenboogaart
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Abstract
Background 
It is uncertain whether thrombolytic therapy is safe in patients with acute ischemic stroke 
who are treated with warfarin and have a subtherapeutic international normalized ratio 
(INR) at stroke onset.
Methods 
The authors performed a systematic review of the literature and included studies that 
assessed the relation between prior warfarin use with subtherapeutic INR and outcome 
after intravenous or intra-arterial thrombolytic therapy in acute ischemic stroke. Outcome 
measures were symptomatic intracranial hemorrhage (SICH), modiﬁed Rankin scale score 
0-2 and mortality. Second, the authors performed a meta-analysis of the included studies.
Results 
Seven studies with 3631 patients were included. 240 (6.6%) patients used warfarin before 
stroke onset. The risk of SICH was increased in the warfarin group (OR 2.6; 95% CI 1.1 to 
5.9. p 0.02). There was no signiﬁcant difference, however, in functional outcome (OR 0.9; 
95% CI 0.6 to 1.2, p 0.32) or death from all causes (OR 1.2; 95% CI 0.9 to 1.8).
Discussion 
The risk of SICH after thrombolytic therapy is increased in patients using warfarin with 
subtherapeutic INR levels. The authors found no evidence of an increase in death from all 
causes or worsening of functional outcome in warfarin treated patients.71
Thrombolytic therapy for ischemic stroke in patients using warfarin: as systematic review and meta-analysis
Introduction
The treatment of acute ischemic stroke with recombinant tissue plasminogen activator 
(tPA) improves functional outcome. (5) A feared and often devastating complication of tPA 
treatment is the occurrence of symptomatic intracranial hemorrhage (SICH). An important 
clinical consideration for stroke physicians is to identify which patients are at risk for 
developing SICH after tPA treatment. Since the introduction of tPA, several predictors for 
good functional outcome and SICH have been elucidated on which current guidelines are 
based. 6-9  There is much controversy whether to treat ischemic stroke patients using 
warfarin with suboptimal international normalized ratio (INR). While the American Heart 
Association guidelines suggest treating patients with an INR <1.7, 1  the European Stroke 
Organisation guidelines discourage the use of tPA in patients treated with warfarin 
regardless of the INR. 10 
A number of cohort studies investigated the safety of tPA in this subgroup of warfarin 
treated patients, but the results were conﬂicting. 2-4,11-14  Some investigators found an 
increased risk of SICH and/or poor clinical outcome, whereas others found no important 
differences regarding clinical outcome and risk of SICH. Many of these studies had 
insufﬁcient power because of small sample sizes. 
The aim of this study was to perform a systematic review and meta-analysis of studies that 
investigated the relation between prior warfarin use with subtherapeutic INR and outcome 
after thrombolytic therapy in patients with acute ischemic stroke.
Methods
Literature search
We searched in Medline and Embase for the MeSH terms ‘isch(a)emic stroke’ and 
‘thrombolysis’ or ‘tissue plasminogen activator’ or ‘thrombolytic therapy’ and ‘warfarin’ or 
‘vitamin K antagonist’. We selected only studies that were written in English. Based on the 
abstracts we included the relevant studies. References of the included studies were 
thoroughly searched to ﬁnd potentially relevant citations.
Eligibility criteria
We used the following inclusion criteria: 1  Studies comparing acute stroke patients with 
and without prior warfarin therapy treated with intravenous tPA or/and intra-arterial 
thrombolytic therapy. 2  Available outcome measures: modiﬁed Rankin scale (mRS) score at 
3 months, SICH and/or death from all causes. SICH had to be deﬁned as an intracranial 
hemorrhage (parenchymal hemorrhage or hemorrhagic transformation) with neurological 
deterioration. We excluded case reports, non-comparative case series and studies that only 
treated patient with mechanical thrombectomy.
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Data collection
Available baseline characteristics such as age, National Institutes of Health Stroke Scale 
(NIHSS) score, INR values and treatment modality (intravenous and/or intra-arterial 
thrombolysis) were extracted from the studies by two investigators (IM and MU). In case 
of disagreement, consensus was obtained by discussion with the other authors. When 
available, data about recanalization rates (TIMI (thrombolysis in myocardial infarction 
score) grade 2-3 or TIBI (thrombolysis in brain ischemia) grade 4-5) after treatment were 
also obtained. Results from our own centre, were also added to the meta-analysis. 15  
Statistical analysis
For the meta-analysis, data from the included studies were collected and ORs for the three 
different outcome measures were calculated using the Mantel-Haenszel method with ﬁxed 
effect models. Heterogeneity between the studies was assessed with the I2 statistic. In case 
of signiﬁcant heterogeneity (p<0.05), random effect models were used. Sensitivity analyses 
were performed with exclusion of studies with slightly different deﬁnitions of SICH/
mortality. The statistical analyses were performed with Review Manager 5.1 (Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collaboration, 2011).
Results
Literature search
Based on our search strategy, we found 147 studies in the literature, of which nine were 
potentially relevant after screening the abstracts/titles. 2-4,11-14,16,17  Two studies were excluded 
for the meta-analysis because of small case series with a non-comparative design  2,14  and 
one study was excluded because patients were only treated with mechanical thrombectomy. 17  
The total number of patients in the pooled dataset was 3631, of whom 240 (6.6%) used 
warfarin before stroke onset. The characteristics of the studies are presented in Table 1. 
Most studies were retrospective analyses of prospectively collected data. One study 
primarily compared elevated INR with normal INR instead of warfarin/no warfarin use. 16  
Most studies excluded patients with INR levels >1.7. One study reported nine tPA treated 
patients with an INR >1.7, and none of these patients developed SICH. 16  Patients with 
warfarin therapy were older and had more severe strokes in most studies. SICH was deﬁned 
as an increase in NIHSS score of four or more points and a parenchymal hemorrhage 
within 36 h after treatment, except for one study which did not specify the degree of 
neurological deterioration on the NIHSS. 12  Two studies did not assess functional outcome 
with the mRS, 4,16 and one study assessed functional outcome at discharge. 12 The remaining 
studies reported 3 months functional outcome, deﬁning favorable outcome as mRS score 
of 0-2. Kim et al 3  published mortality rates at 3 months. The other studies only reported 
in-hospital mortality. Two studies assessed recanalization rates using conventional 
angiography, MR angiography or transcranial Doppler. Both studies did not ﬁnd a signiﬁcant 
difference in recanalization rates between the two groups (Table 2).73
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Table 1: Characteristics of the included studies.













Kim (3) RS analysis 
PS cohort 179 Warfarin vs no warfarin
28 / 151 1.14 vs 0.99 17 vs 16.5  69.2 vs 68.5 IV tPA +/- IA 
urokinase
Vergouwen (12) RS analysis 
PS cohort 1739 Warfarin vs no warfarin
125/1614 1.2 vs 1.0 14 vs 12  79 vs 74 (median) IV tPA
Ibrahim (13) RS of phase 
2 trial 284 Warfarin vs no warfarin
9 / 180 - 15 vs 15.8
(Mean) 72 vs 68.3 IV tPA
Prabhakaran (4) RS analysis 
PS cohort 107 Warfarin vs no warfarin
13/94 1.21 vs 1.03 15 vs 14 80.6 vs 67.6 IV tPA
Brunner (16) RS analysis 
PS cohort 688 Elevated vs normal INR
29 / 659 1.5 vs ? * 13 vs 11  73 vs 72 IV tPA
Seet (11) not clearly 
described 212 Warfarin vs no warfarin
14 / 198 1.15 vs 1.0 13 vs 13  79 vs 74 IV tPA
Miedema (15) RS analysis 
PS cohort 524 Warfarin vs no warfarin






Table 2: Outcome of the included studies
First Author
All ICH
( % Warfarin vs 
no warfarin)
Symptomatic ICH 
(% Warfarin vs 
no warfarin)
mRS 0-2
(% Warfarin vs no 
warfarin)
Mortality
(% Warfarin vs no 
warfarin)
Recanalisation
(% Warfarin vs no 
warfarin)
Kim (3) 37 vs 31.5 14.8 vs 8.1* 51.9 vs 40.7 18.5 vs 20.7‡ 92 vs 85
Vergouwen (12) 16.8 vs 11.1 8 vs 5.7† 26.8 vs 31.3 19.2 vs 16.1§ -
Ibrahim (13) - 0 vs 5* 55.6 vs 53.1 55.6 vs 38.2
Prabhakaran (4) 38.5 vs 5.3 30.8 vs 3.2* - 15.4 vs 9.6§ -
Brunner (16) 5.6 vs 7.7 0 vs 4.4* - 8.3 vs 8.8§ -
Seet (11) 43 vs 14 36 vs 6* 29 vs 52 36 vs 19§ -
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Outcome and meta-analysis
Symptomatic ICH
In two studies, prior warfarin therapy was signiﬁcantly associated with SICH. 4,11  In the 
other ﬁve studies, there was no signiﬁcant difference between incidence of SICH in patients 
with and without warfarin therapy, although 95% CIs of most studies were wide. The risk 
of any ICH after tPA in patients with prior warfarin was substantially higher in two studies, 
whereas in the other ﬁve studies the rates were rather similar in both groups (Table 2).
The meta-analysis demonstrated a signiﬁcant degree of heterogeneity between the studies 
(Figure 1A). In the pooled analysis, prior warfarin use was signiﬁcantly associated with 
SICH (OR 2.6; 95% CI 1.1 to 5.9. p=0.02). Excluding the study from Vergouwen et al 12 
who used a slightly different deﬁnition of SICH, the same signiﬁcant association was 
yielded (OR 3.0; 95% CI 1.1 to 8.4, p=0.03). 
Functional outcome
Five studies reported 3-month functional outcome with the mRS from which the number 
of patients with a favorable outcome (mRS 0-2) could be extrapolated (Table 2). 3,11-13,15   
None of the studies showed a signiﬁcant relation between prior warfarin use and good 
outcome after tPA. There was no signiﬁcant heterogeneity between the studies (Figure 1B). 
The pooled OR from the meta-analysis did not demonstrate a signiﬁcant relation between 
favorable functional outcome and prior warfarin use (OR 0.9; 95% CI 0.6 to 1.2, p=0.32).
Mortality
One study did not report data about mortality; Kim et al 3  reported 3-month mortality and 
the other ﬁve studies assessed the in-hospital mortality (Table 2). No differences were 
found in the in-hospital mortality between patients with and without prior warfarin therapy 
(OR 1.2; 95% CI 0.9 to 1.8, p=0.28) (Figure 1C). Excluding the study of Kim et al 3  that 
reported mortality at 3 months did not alter the results (OR 1.3; 95% CI 0.9 to 1.9, p=0.28).
Discussion
The main ﬁnding of this meta-analysis was an increased risk of SICH in patients with acute 
ischemic stroke and prior warfarin therapy with a subtherapeutic INR after treatment with 
intravenous and/or intra-arterial thrombolysis. The risk of SICH was more than two times 
higher in patients on warfarin therapy compared with those without. However, there was 
no evidence that prior warfarin therapy was associated with (un)favorable outcome or an 
increase in death from all causes. Most of the included studies concerned patients treated 
with intravenous tPA, and few studies were done in patients receiving endovascular 
treatment. A reanalysis of the MERCI (Mechanical Embolus Removal in Cerebral Ischemia) 
and multi-MERCI trials 17  demonstrated that mechanical thrombectomy in patients with 75
Thrombolytic therapy for ischemic stroke in patients using warfarin: as systematic review and meta-analysis
Figure 1: Meta-analysis of outcome in patients with and without warfarin treated with thrombolysis 
ICH: intracranial hemorrhage, mRS: modiﬁed Rankin Scale. 
(A) Symptomatic ICH random effect models
(B) Favorable functional outcome (mRS 0-2), ﬁxed effect models
(C) Mortality, ﬁxed effect models
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acute ischemic stroke and prior warfarin use with an INR larger than 1.7 was also associated 
with SICH. 
During acute cerebral ischemia the blood brain barrier becomes damaged, which can lead 
to spontaneous hemorrhagic transformation. 18  Disruption of the blood brain barrier is 
inﬂuenced by several proteolytic enzymes, such as matrix metalloproteinases (MMP). 19 In 
acute ischemic stroke, tPA treatment is associated with an up-regulation of MMP-9 and 
may therefore enhance the risk of SICH. 20  Reperfusion also enhances the risk of SICH.  21  
Animal experiments have demonstrated that warfarin increases the risk of hemorrhagic 
transformation in acute ischemia, which was highly dependent on reperfusion. 22  So, a 
combination of reperfusion injury, up-regulation of MMP-9 and strong anticoagulant effect 
of warfarin might explain the observed increased risk of SICH. The same effect has been 
observed in patients treated with antiplatelets before tPA treatment. 8,23  
On the other hand, a common problem after thrombolytic therapy is the occurrence of 
early re-occlusion. Some have hypothesized that recanalization rates with warfarin may be 
better than without warfarin, although this idea was not conﬁrmed by two of the included 
studies (Table 2). 3,13  A topic of interest is whether newer anticoagulants, such as dabigatran 
etexilate, also increase the risk of SICH. We are only aware of a single case report of an 
acute stroke patient on dabigatran treated with intravenous tPA who did not develop 
hemorrhagic complications. 24 
This systematic review has limitations. First, there were some small differences in the 
deﬁnition of SICH, which could inﬂuence the SICH rates. Moreover, the meta-analysis 
regarding SICH revealed a signiﬁcant heterogeneity between the studies. Most studies 
however used a deﬁnition of intracranial hemorrhage with an NIHSS score increase of four 
or more points. In the sensitivity analysis, excluding the study that used another deﬁnition 
of SICH, the results remained the same; therefore, it seems unlikely that these differences 
inﬂuenced the ﬁnal results. Second, we could not perform multivariate analyses with 
adjustment for possible confounders. Patients with warfarin were older and, as a 
consequence, may have had more often leucoaraiosis. Both age and leucoaraiosis may also 
have contributed to an increased risk of SICH. 25  Patients with warfarin had also more often 
cardio-embolic strokes. It is known that cardio-embolic strokes are associated with larger 
diffusion weighted imaging lesions, which is also a strong predictor of SICH after 
intravenous tPA. 9  Other possible confounders, such as early ischemic changes on brain CT 
or blood pressure values, 26  were not included in our analyses. These imbalances can 
confound the relation between prior warfarin and SICH. Third, we did not have data about 
the INR levels from patients with and without SICH. It could be possible that there is a 
cut-off point for the INR at which the risk of SICH increases. Results from our centre 
suggest that an elevated INR >1.2 was associated with SICH. 15  Vergouwen et al. found no 
association between the INR level and occurrence of SICH. 12  Fourth, only two studies 
documented recanalization rates. It would be interesting to evaluate the degree of 77
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recanalization in patients with and without prior warfarin in a larger sample size. Fifth, it 
may be possible that, due to publication bias, the risks of hemorrhagic complications after 
thrombolytic therapy in patients with warfarin treatment were underestimated.
In summary, this study suggests that patients on warfarin therapy, but with subtherapeutic 
INR, have an increased risk of SICH after thrombolytic therapy. However, we did not 
observe an association between prior warfarin therapy and a worse functional outcome or 
increase in death from all causes. Further studies should focus at which INR cut-off score 
the risk of SICH increases.
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Summary and integrated discussion
In the last two decades, the development of revascularization therapy with intravenous 
recombinant tissue plasminogen antigen (tPA) has greatly improved the outcome in acute 
ischemic stroke patients, but this therapy is only available for a selected group of patients 
and even in eligible patients, it is underused. 1-5  But treatment with intravenous tPA has 
also safety concerns with several contra-indications and an increased risk of intracranial 
hemorrhage. 1,3,12  In addition to revascularization therapy, neuroprotective strategies need 
to be developed to improve functional outcome by acting on the ischemic penumbra, but 
results from randomized controlled trials in humans have been uniformly disappointing.   
6-11 
Neuroprotection
In Chapter 2 and 3 the potential neuroprotective effects of selective serotonin re-uptake 
inhibitors (SSRIs) and statins (HMG-CoA reductase inhibitors) were investigated. For both 
drugs, pleiotropic effects have been found in pre-clinical studies. 13-18  Based on these 
preclinical ﬁndings, the idea arose that these drugs could be neuroprotective in acute 
ischemic stroke. In human clinical cohorts conﬂicting results were reported. 16,19-26 We 
studied the relation between these drugs and functional outcome in an observational 
cohort study with a prospectively collected dataset of patients, whose acute ischemic stroke 
was treated with intravenous tPA within 4.5 hours of symptom onset. 
In patients, the use of SSRIs, started in the ﬁrst weeks till months after the ischemic stroke, 
has been shown to be associated with improved functional outcome, possibly by pleiotropic 
effects on brain plasticity. 19,20  Chronic use of SSRIs enhances the concentration of brain-
derived neurotrophic factor (BDNF) which plays a part in neurite outgrowth, synaptic 
plasticity and the selection of functional neuronal connections. 27-29  Contrary to these 
ﬁndings, we found (Chapter 2) a detrimental effect on functional outcome in patients who 
used a SSRI prior to stroke onset. This effect was strongest in patients with a cortical stroke. 
The discrepancy with previous results could be explained by the effects of elevated BDNF 
in chronic SSRI users which also increases the release and sensitivity of glutamate. 30 
Glutamate plays a major role in excitotoxicity in de acute phase of ischemic stroke. 11 
Therefore, SSRIs may be more regenerative than neuroprotective, with improved functional 
outcome when prescribed in the late phase of ischemic stroke, while in the acute phase it 
could be harmful to patients treated with intravenous tPA. Additional research to explore 
these various potential effects is warranted. 
A large meta-analysis on the efﬁcacy of statins in animal stroke models supports the 
neuroprotective effect of statin. These drugs appear to inﬂuence infarct volume (reduction 
of 25%) as well as improvement of neurological recovery (improvement up to 20%). 22 In 
patients treated with intravenous tPA, one study showed a beneﬁcial effect of statins on 83
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functional outcome 25 , but other studies could not replicate this. A detrimental effect of 
statins was even suggested, with a higher risk of symptomatic intracranial hemorrhage 
(SICH). 23-26,31,32  This latter ﬁnding remains unexplained although it is sometimes cross-
connected to serum lipid levels. 23,26,32  As described in Chapter 3, we found neither a 
beneﬁcial nor a detrimental effect of prior statin use on functional outcome. Our results do 
not support a neuroprotective effect of statins in acute ischemic stroke patients treated with 
intravenous tPA. In line with our results, a large pooled analysis of 11 databases including 
4000 patients, conﬁrmed that prior statin use was neither associated with functional 
outcome nor with intracranial hemorrhage, but it may be considered as an indicator of 
baseline cardiovascular characteristics that are associated with a less favorable course. 33 In 
contrast, an other large recent observational multicenter study that included 2000 patients 
found statin use in the acute phase of stroke after intravenous thrombolysis to be associated 
with favorable short- and long term outcome. 34 In this trial the subgroup of statin users 
differed signiﬁcantly from the no-statin group with regard to several prognostic baseline 
factors, like stroke severity. Thus, the verdict on the issue is still open, awaiting the 
randomized controlled trials that at this moment are lacking.
In Chapter 4, the effects of serum uric acid concentrations on functional outcome after 
acute ischemic stroke have been discussed. On the one hand uric acid supports the 
development and progression of atherosclerosis; on the other hand it acts as a powerful 
anti-oxidant. 35-37  Uric acid can be administrated safely in human subjects, thus increasing 
anti-oxidant capacity. 38  In animal models administration of uric acid has been proven to 
be neuroprotective. 39,40  In clinical cohort studies a neuroprotective effects of uric acid was 
suggested, while other cohort studies reported an association with poor outcome. 41-48 We 
investigated the effect of serum uric acid concentrations on functional outcome in a cohort 
of prospectively collected patients with acute ischemic stroke who were not treated with 
intravenous tPA. We failed to demonstrate a neuroprotective effect of uric acid. One 
hypothesis could be that the neuroprotective effect in the acute phase of the initial stroke 
is obscured by preexistent more severe cardiovascular disease in these patients with higher 
serum uric acid levels. This would impact ﬁnal outcome.  
For all three potentially neuroprotective agents investigated in Chapters 2, 3 and 4 of this 
thesis we failed to identify actual neuroprotective effects. For the SSRIs we even found a 
relation with poor functional outcome. As described earlier, several factors may be held 
responsible for these disappointing results. Some of them need to be addressed here.
There are large difference between the methodology and results from animal experiments 
and trials in humans. In animal studies histological stained infarct volume is most 
commonly used as the primary end-point for a neuroprotective effect. In human studies, 
neuroprotection is most commonly assessed by clinical functional outcome. The 
neuroprotective effect on the ischemic penumbra in human patients may be too small to 
result in a signiﬁcant difference in the ‘crude’ outcome scales that are being used. Functional 
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imaging modalities like diffusion/perfusion MRI may ultimately yield signiﬁcant differences, 
without effects on functional outcome, and thus no clinical consequences. Secondly, the 
pleiotropic effects of the agents investigated may not be only beneﬁcial, but they may also 
be harmful, protective effects being counteracted by detrimental effects. Thirdly, in the 
entire spectrum of neuroprotective research in ischemic stroke the vast array of 
methodological differences between animal and human clinical studies have been 
considered to be responsible for the lack of translational success of neuroprotective 
agents.  49,50  It has been questioned whether the most efﬁcacious agents were selected for 
clinical trials. 49  Proposed methodological differences are dosage regimens, time of 
administration of the agent, route of administration and availability to the target area. 50,51  
In this thesis, only observational cohort studies were performed, no actual intervention 
trials. A population of patients who already used the drugs of interest at the onset of stroke 
was studied. This mimics to some extent the setting of the pre-clinical animal trials, where 
drug administration is usually started pre-stroke or early after stroke initiation. although 
from a methodological point of view major differences still exist with these pre-clinical 
trials. The observational nature of the studies in this thesis is far from ideal for the clinical 
investigation of neuroprotective agents, but based on observational data, one would hope 
to ﬁnd at least an association with functional outcome. 
With regard to statins results are conﬂicting. Recently an association with favorable short- 
and long term functional outcome. 34  The only way to answer this question is to perform a 
large clinical trial. But still, even if a neuroprotective effect of statin use will be found, we 
expect it to be small, as it has already been extensively researched in observational studies, 
which yielded mainly neutral results. 
Neurotoxicity
Hyperglycemia is a known risk factor for the development of SICH and poor outcome in 
patients with acute ischemic stroke. In patients with acute stroke who were not treated 
with thrombolysis, a differential effect of admission hyperglycemia on outcome was found, 
depending upon stroke subtype: poor outcome in non-lacunar stroke and a more favorable 
outcome in lacunar stroke with moderate hyperglycemia. 52,53  Chapter 5 examines whether 
this ﬁnding could be reproduced in patients treated with intravenous tPA. It appeared that 
hyperglycemia was associated with poor functional outcome in both lacunar and non-
lacunar stroke. Possibly, in patients with lacunar stroke treated with intravenous tPA the 
exposure to reperfusion injury aggravated by hyperglycemia is the same as in patients with 
non-lacunar stroke. These effects may counterbalance the suggested protective effects of 
hyperglycemia in lacunar stroke patients. No signiﬁcant difference in occurrence of SICH 
between hyperglycemic and normoglycemic patients in either stroke subtype was found, 
probably because of the low number of SICH in the study population. 85
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Safety of tPA treatment
The safety and efﬁcacy of tPA treatment has been proven in various large randomized 
controlled trials, but tPA treatment remains associated with an increased risk of intracranial 
and systemic bleeding complications. 1-5,12  Several factors clearly enhance the risk of 
intracranial hemorrhage, like age and stroke severity. Data on the safety of tPA treatment in 
patients with prior use of vitamin K antagonists and subtherapeutic INR are contradictory.   
54,55  These patients are considered eligible for intravenous thrombolysis but may have an 
increased risk of bleeding complications. In our prospective observational study on the 
risk of symptomatic intracranial hemorrhage (SICH) in patients treated with intravenous 
tPA and prior use of vitamin K antagonists and/or elevated INR presented in the ﬁrst part 
of Chapter 6, we found that prior treatment with vitamin K antagonists at the moment of 
acute ischemic stroke, with a normal or slightly elevated INR (<1.7), was associated with 
an increased risk of SICH. However, there was no association of prior use of vitamin K 
antagonists and/or elevated INR with poor functional outcome. In the second part of 
Chapter 6, a systematic review of the current literature and a meta-analysis of this subject 
was performed, combining results of our own observational study with those of other 
observational cohort studies. This meta-analysis demonstrated that prior use of vitamin K 
antagonists is signiﬁcantly associated with the risk of intracranial hemorrhage. But no 
association with functional outcome and in-hospital mortality could be found. Recently, 
the results of a large observational study including more than 20.000 patients on this topic 
have been published. 56  No increased risk was found of SICH among patients with acute 
ischemic stroke and prior use of vitamin K antagonists before treatment with thrombolysis. 
Although these results represent the largest experience on safety of thrombolysis in patients 
with prior use of vitamin K antagonists, this study should be interpreted with caution. 
Differences in methods and patient selection need to be considered in explaining the 
discrepancy among the studies. 57,58  Therefore, despite the heterogeneity between the 
various studies in the meta-analysis and despite the ﬁnding that prior use of vitamin K 
antagonists does not inﬂuence the actual functional outcome at three months after the 
acute ischemic stroke, the increased risk of intracranial hemorrhage makes it important to 
be careful with intravenous thrombolysis in patients with prior use of vitamin K antagonists 
and a subtherapeutic INR. 
Patients who used vitamin K antagonists prior to acute ischemic stroke are likely to suffer 
more often cardio-embolic strokes, due to their underlying conditions which required 
vitamin K antagonists in the ﬁrst place. As known from the literature, cardio-embolic 
strokes are associated with larger infarct size;  they constitute a risk factor for SICH. 59,60 
Therefore, the assumed association of higher SICH rates in these patients may be 
confounded by the higher incidence of cardio-embolic stroke, in addition to the effects of 
vitamin K antagonists itself and the combination of vitamin K antagonists with thrombolysis, 
as discussed in Chapter 6. 
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Future perspectives
In acute ischemic stroke rapid restoration of blood ﬂow by thrombolysis, with resupply of 
oxygen and glucose is currently the most effective form of neuroprotection. In the last 
decades, over 1000 other neuroprotective agents have been tested in pre-clinical stroke 
trials. 49  Around 200 clinical trials investigating the effects of neuroprotective agents have 
been performed or are still ongoing, nearly all yielding disappointing results. 49  The 
observational studies in this thesis could not demonstrate a neuroprotective effect of the 
compounds studied. In the perspective of this large amount of negative trials, the question 
arises whether it is justiﬁed to continue further research on this topic. Future research 
should be well designed and well targeted. To better translate promising pre-clinical 
neuroprotective agents to clinical application, bridging the methodological differences 
between animal and human studies is necessary. In the design of pre-clinical experiments 
and trials, population type (age, co-morbidity), ischemic territory, duration of occlusion 
and dosage regimens are examples of factors that should be addressed. 51,61  Furthermore, 
outcome parameters should be carefully considered, with functional outcome, rather than   
infarct size as the main parameter. Even with these changes, it is questionable whether the 
translation of animal ischemic stroke models into the clinical setting will be successful. 
A new treatment modality that addresses  neuroprotection in patients with acute ischemic 
stroke is hypothermia, which is known to improve outcome in patients with post-anoxic 
encephalopathy. This therapy showed no beneﬁcial effects in traumatic encephalopathy. At 
the moment trials assessing the possible therapeutic effect of hypothermia in combination 
with revascularization therapy are ongoing. 62 
Identiﬁcation of patients who will obtain most beneﬁt from intravenous tPA treatment or 
are at high risk for the development of complications remains a crucial goal. This thesis 
conﬁrmed that admission hyperglycemia is associated with poor outcome in patients 
treated with intravenous tPA irrespective of infarct subtype. The next logical step would be 
to investigate the role of intervention with glucose lowering strategies in such patients. At 
this moment glucose lowering intervention studies have been unable to provide evidence 
that tight glycemic control improves functional outcome in patients with acute ischemic 
stroke. 63,64  Timing of glucose management, ideally before reperfusion is complete and 
therefore before treatment with tPA, maintaining tight glucose levels as well as preventing 
hypoglycemia, are issues that require further research on this topic. The ideal intervention 
should balance safety and beneﬁt, considering that hypoglycemia has also a potential 
detrimental effect on tissue in the already vulnerable ischemic penumbra.
This thesis showed that prior use of vitamin K antagonists in patients with acute ischemic 
stroke treated with intravenous thrombolysis is associated with an increased risk of SICH. 
As conﬂicting data have recently been published 56 , further research on this topic is needed. 
It should not only focus on early occurrence of SICH in vitamin K antagonists users and 
long term functional outcome, but it should also include serial INR data to consider at 
which cut-off point for INR patients are at high-risk of SICH development. This cut-off 87
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point for INR could then be implemented in the current acute ischemic stroke and 
thrombolysis guidelines. The American Heart Association’s current guidelines suggest a 
cut-off point of INR <1.7, which is not in line with the European Stroke Organisation 
guidelines that discourage the use of thrombolysis in all patients using vitamin K 
antagonists. 55,65  With the upcoming use of new oral anticoagulants like dabigatran etexilate 
and rivaroxiban, the effects and risks of these drugs in patients with acute ischemic stroke 
treated with thrombolysis need to be re-assessed. 
Main conclusions
The ﬁeld of neuroprotection in acute ischemic stroke is an relevant subject of research with 
promising results from pre-clinical trials. Unfortunately,  in the clinical setting these 
successes can not be reproduced. The data presented in this thesis also do not support a 
neuroprotective effect of selective serotonin re-uptake inhibitors, statins and serum uric 
acid. It is questionable whether the development of better adjusted pre-clinical and clinical 
trials with neuroprotective agents in general would easily overcome these limitations. Until 
that time treatment with intravenous thrombolysis remains the most effective therapy for 
acute ischemic stroke. However, selection of patients to reduce the risks of hemorrhagic 
complications is a major issue. Use of vitamin K antagonists, elevated INR and hyperglycemia 
are associated with the occurrence of SICH and with poor functional outcome, respectively. 
The widespread use of vitamin K antagonists and the high incidence of admission 
hyperglycemia in patients with acute ischemic stroke prioritizes these factors for further 
research. But from the broader perspective of neuroprotection and safety of tPA treatment, 
the question remains whether inﬂuencing only a single factor would improve overall 
outcome in patients with acute ischemic stroke, as acute ischemic stroke has multiple 
causes and occurs in often frail patients with  extensive co-morbidity. 
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Nederlandse samenvatting
Het herseninfarct is een vaak voorkomend ziektebeeld met frequent overlijden tot gevolg. 
Ondanks de afnemende incidentie in de afgelopen jaren en daling van mortaliteit, is de 
verwachting dat de prevalentie en kosten in de komende jaren juist toenemen mede door 
groei van de oudere populatie bij een langere levensverwachting. De ontwikkeling van 
revascularisatie-therapie met recombinant tissue plasminogen activator (tPA, verder 
genoemd trombolyse) heeft reeds geleid tot een verbetering van de uitkomst en vermindering 
van beperkingen na een herseninfarct. Het effect van trombolyse is het meest duidelijk bij 
vroegtijdige toediening van het medicijn, waarbij de meeste effectiviteit, met een number 
needed to treat (NNT) van 5, is aangetoond wanneer het wordt toegediend in de eerste 90 
minuten na aanvang van de verschijnselen. Het belangrijkste risico van trombolyse is de 
ontwikkeling van een symptomatische intracraniële bloeding. Vanwege het relatief korte 
tijdsbestek waarin de behandeling effectief is, komt er in de praktijk slechts een deel van 
de patiënten in aanmerking voor deze therapie. Daarnaast bepalen ook een aantal contra-
indicaties de toepasbaarheid van trombolyse in de dagelijkse praktijk, zoals een verhoogde 
glucose waarde, gebruik van anti-stollingsmedicatie en een verhoogde bloeddruk. 
Een andere strategie om de uitkomst na een herseninfarct te verbeteren is de ontwikkeling 
van neuroprotectiva. Neuroprotectie verwijst naar een positief effect van medicatie of 
andere stoffen op de neuronale overleving na cerebrale ischemie. Na het acute moment van 
ischemie begint er een ischemische cascade waarbij activatie van diverse stoffen, waaronder 
ionen en neurotransmitters, uiteindelijk leidt tot irreversibele schade aan de neuronen en 
daarmee celdood. In de afgelopen jaren zijn verschillende neuroprotectieve stoffen 
onderzocht. Preklinische studies lieten hierbij vaak veelbelovende resultaten zien, maar de 
vertaling naar klinische fase III onderzoeken lijkt niet goed te lukken. Factoren die 
hoogstwaarschijnlijk hierin een rol spelen zijn bijvoorbeeld methodologische verschillen 
en verschillen in doseringen en tijdstip van toedienen van de stoffen. Daarnaast simuleert 
de setting van diermodellen met een herseninfarct waarschijnlijk onvoldoende de klinische 
setting bij de mens. Ondanks deze tegenvallende resultaten, blijft het concept van 
neuroprotectie veelbelovend klinken. Daarom wordt toch verder onderzoek gedaan naar 
de mogelijkheden van neuroprotectie, deels met gebruik van combinatie van verschillende 
therapieën waarbij gedacht wordt dat niet alleen de uitkomst na een herseninfarct kan 
verbeteren, maar mogelijk ook het aantal patiënten wat in aanmerking komt voor 
trombolyse zou kunnen toenemen. 
In dit proefschrift is het effect onderzocht van een aantal mogelijke neuroprotectieve stoffen 
op de klinische uitkomst bij patiënten met een doorgemaakt herseninfarct behandeld met 
trombolyse. Ook is gekeken naar andere prognostische factoren die de therapeutische 
effecten en veiligheid van trombolyse zouden kunnen verbeteren. 95
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In Hoofdstuk 2 en 3 werd het potentiële neuroprotectieve effect van selective serotonine 
re-uptake inhibitors (SSRI’s) en HMG-CoA reductase inhibitors (statines) onderzocht. In 
een observationele cohort studie van prospectief verzamelde patiëntgegevens werd de 
relatie onderzocht tussen het gebruik van één van de medicamenten met de functionele 
uitkomst van patiënten met een acuut herseninfarct behandeld met trombolyse. Eerder 
onderzoek had laten zien dat het starten van een SSRI in de eerste weken tot maanden na 
een acuut herseninfarct geassocieerd was met een betere uitkomst. Het bleek echter dat de 
functionele uitkomst van patiënten met een herseninfarct die reeds vooraf aan het 
herseninfarct een SSRI gebruikten juist slechter was, met name bij patiënten met een 
corticaal infarct. Het gebruikt van een SSRI lijkt dus geen neuroprotectief effect te hebben. 
De mogelijke verklaring hiervoor wordt besproken in Hoofdstuk 2. Het toedienen van 
statines heeft in diermodellen een neuroprotectief effect laten zien. Er werd zowel een 
kleiner infarct volume als een verbetering van neurologisch herstel gezien. Patiëntgebonden 
studies hebben een enkele maal een neuroprotectief effect aangetoond, maar regelmatig 
werd dit ook niet gevonden. In de studie beschreven in Hoofdstuk 3 werd ook geen effect 
gevonden van het gebruik van een statine op de uitkomst na een herseninfarct behandeld 
met trombolyse. In de recente literatuur blijft er veel discussie bestaan over het mogelijke 
neuroprotectieve effect van statines doordat er tegenstrijdige onderzoeksresultaten 
gepubliceerd worden. Het ontbreekt nog aan een grote gerandomiseerde studie om het 
vraagstuk op te lossen. 
Urinezuur is één van de meest krachtige natuurlijke anti-oxidanten en zou daarom een 
neuroprotectief effect hebben, zoals ook aangetoond in diermodellen. Urinezuur is echter 
ook geassocieerd met een hoger risico op ontwikkeling en progressie van atherosclerose. In 
Hoofdstuk 4 werd het effect van de concentratie urinezuur in het bloed op de uitkomst na 
een herseninfarct onderzocht. Het bleek dat er geen neuroprotectief effect van urinezuur 
kon worden aangetoond. Een verklaring hiervoor zou kunnen zijn dat de mogelijk geringe 
beschermende effecten van urinezuur worden overschaduwd door de meer uitgesproken 
cardiovasculaire comorbiditeit bij deze patiënten. 
Hyperglycemie is geassocieerd met een slechtere uitkomst en een hoger risico op het 
ontwikkelen van een symptomatische intracraniële bloeding na een herseninfarct. Bij 
patiënten met een acuut herseninfarct niet behandeld met trombolyse werd eerder juist een 
positief effect van een milde hyperglycemie beschreven bij patiënten met een lacunair 
infarct. Hoofdstuk 5 beschrijft de studie waarin gekeken werd of dit ook gold voor infarcten 
behandeld met trombolyse. Het bleek echter dat hyperglycemie bij trombolyse in zowel 
lacunaire als corticale infarcten geassocieerd was met een slechtere uitkomst. 
Het is onduidelijk of het veilig is om een patiënt die orale anticoagulantia gebruikt en een 
subtherapeutische international normalized ratio (INR) heeft te behandelen met trombolyse. 
De richtlijn van de American Heart Association suggereert om patiënten met een INR <1.7 
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te behandelen, de richtlijn van de European Stroke Organisation ontmoedigt het gebruik 
van trombolyse bij alle patiënten die orale anticoagulantia gebruik, onafhankelijk van de 
INR. Verschillende cohort studies hebben de veiligheid van trombolyse in combinatie met 
gebruik van anticoagulantia onderzocht, maar de gevonden resultaten waren tegenstrijdig: 
een toegenomen risico op bloeding en slechte uitkomst tegenover geen aantoonbaar 
verschil. Vaak betrof het een kleine onderzoekspopulatie. In Hoofdstuk 6 werd geprobeerd 
meer duidelijkheid hierover te verkrijgen. Het bleek dat gebruik van orale anticoagulantia 
met een normale of licht verhoogde INR (<1.7) was geassocieerd met een verhoogd risico 
op het ontwikkelen van een bloeding na trombolyse. Er werd echter geen relatie met de 
functionele uitkomst gevonden. Deze resultaten werden vervolgens gecombineerd met 
eerdere resultaten van andere studies in een meta-analyse. In de meta-analyse werd tevens 
een verhoogd risico op het krijgen van een bloeding na trombolyse gevonden, maar 
opnieuw geen relatie met de uitkomst na het herseninfarct. Er werd geconcludeerd dat 
voorzichtigheid geboden is bij het trombolyseren van patiënten met gebruik van orale 
anticoagulantia en een INR <1.7, maar dat verder onderzoek nodig is om onder andere het 
exacte afkappunt van de INR waarboven het risico toeneemt te bepalen. 
Onderzoek naar neuroprotectie bij herseninfarcten is een interessant onderwerp met 
veelbelovende resultaten in diermodellen. In de klinische setting kunnen deze resultaten 
helaas niet goed worden gereproduceerd. De studies in dit proefschrift naar SSRI´s, statines 
en serum concentraties urinezuur hebben ook geen neuroprotectief effect van deze stoffen 
kunnen aantonen. Tot op heden is behandeling met trombolyse de meest effectieve therapie 
voor patiënten met een acuut herseninfarct. Een goede selectie van patiënten om zo het 
risico op een bloedingscomplicatie of een slechtere uitkomst te verminderen is belangrijk. 
De aanwezigheid van een hyperglycemie ten tijde van de behandeling met trombolyse is 
geassocieerd met een slechtere uitkomst na het herseninfarct, ongeacht het type 
herseninfarct. Het gebruik van orale anticoagulantia met een normale tot licht verhoogde 
INR is geassocieerd met een hoger risico op een intracraniële bloeding, zonder dat dit de 
uitkomst beïnvloedt. De hoge incidentie van hyperglycemie en het frequente gebruik van 
orale anticoagulantia bij patiënten met een herseninfarct maakt verder onderzoek naar 
deze factoren noodzakelijk. Vanuit een breder perspectief blijft het de vraag of beïnvloeding 
van slechts een enkele factor de uitkomst na een herseninfarct voldoende zal kunnen 
verbeteren om een klinisch signiﬁcant effect te kunnen meten; de oorzaak van een 
herseninfarct is vaak multi-factorieel bepaald en het betreft meestal kwetsbare patiënten 
met uitgebreide co-morbiditeit. 97
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Dankwoord
Dit proefschrift was nooit verschenen zonder de hulp, begeleiding en steun van velen. 
Graag wil ik een aantal van hen speciﬁek benoemen. 
Gert-Jan, als co-promoter ben je erg belangrijk geweest in de afgelopen periode. Als jonge 
co-assistent begon ik onder jouw supervisie aan mijn semi-arts stage om vervolgens verder 
te gaan met een wetenschappelijke stage als afronding van mijn studie. Al snel kwam de 
mogelijkheid tot een promotie-traject ter sprake, waarbij ik nooit vergeet dat jij zei dat “ik 
eerst maar moest kijken of ik het deeg kneden leuk vond, voordat ik een taart ging bakken”. 
Nu, ruim 3 jaar later, is de taart af! Ik waardeer je gedrevenheid voor de neurologie en het 
wetenschappelijk onderzoek en je inzet bij het schrijven van al deze hoofdstukken 
waardoor ik enthousiast door bleef werken. Altijd hield je de vinger aan de pols, waarbij je 
regelmatig kort even kwam binnenlopen om een praatje te maken en te kijken hoe het 
ging. Ik wil je bedanken voor al je begeleiding en hoop dat onze samenwerking na dit 
proefschrift niet eindigt. 
Maarten, ik ben er trots op jouw eerste ‘promovendus’ te zijn! In de afgelopen jaren heb ik 
veel van je geleerd. Ik waardeer je tomeloze inzet, waarbij ik altijd bij je terecht kon voor 
een korte of langere vraag en stukken altijd snel van uitgebreid commentaar werden 
voorzien. Wanneer ik er weer eens niet uit kwam met SPSS, wist jij altijd de oplossing te 
vinden. In de afgelopen jaren is er veel voor jou veranderd, zo werk jij nu als staﬂid hier 
op de afdeling met een drukke agenda, maar je begeleiding is er nooit minder intensief om 
geworden. Dankjewel!
Prof. Dr. H.P.H. Kremer, bedankt voor uw begeleiding bij het tot stand komen van het 
proefschrift en het vertrouwen dat u mij hebt gegeven om enkele weken vrij gepland te 
worden om mij volledig te kunnen richten op het schrijven van de verschillende 
hoofdstukken.
Daarnaast wil ik Prof. Dr. J. De Keyser bedanken. Beste Jacques, we hebben op afstand met 
elkaar gewerkt en relatief weinig persoonlijk contact gehad. Toch is uw kritische blik altijd 
van groot belang geweest voor de verschillende hoofdstukken van dit proefschrift en hecht 
ik veel waarde aan uw mening en adviezen. 
Prof. Dr. H.W.G.M. Boddeke, Prof. dr. R.J. van Oostenbrugge en Prof. dr. D.J. van 
Veldhuisen: Hartelijk dank voor uw deelname aan de leescommissie en de beoordeling van 
dit proefschrift. 
Zonder de jarenlange inzet van de CVA-research verpleegkundigen van K2 was er nooit 
zo’n grote database vol met patiënten beschikbaar gekomen. Ik wil in het speciaal Nicole, 101
Friedus en Gert noemen: heel erg bedankt voor het registreren van alle patiënten, het 
achterhalen van alle missende uitkomsten en het beschikbaar stellen van de data zodra ik 
weer iets nodig had! 
Tijdens het schrijven van dit proefschrift heb ik altijd met veel plezier gewerkt in de groep 
van AIOS neurologie. Naast hard werken en drukke diensten is er gelukkig genoeg tijd 
over voor andere bezigheden: vliegeren op Schier, inspirerende studie-avonden, après ski 
in Oostenrijk, occipitale prikkeling en natuurlijk de vele vrijdagmiddag borrels. Ik hoop in 
de komende jaren nog veel gezellige momenten met jullie te beleven!
Voor de nodige ontspanning zijn vrienden natuurlijk onmisbaar! Heel erg bedankt voor 
alle gezellige weekenden, dagjes, etentjes en spelletjesavonden. Elke keer zorgt de warmte 
en gezelligheid voor een goede oplaaddosis energie om er weer tegen aan te kunnen! 
Martine, lieve Martine, als ‘achterblijver’ hier in Groningen hebben we de laatste jaren nog 
intensiever contact gehad. Beiden zijn we ook bezig met wetenschap, al is het op een hele 
andere manier. Ik waardeer het dat je mijn paranimf wilt zijn, ook al heb je er iets anders 
voor moeten opofferen. Helaas zul je waarschijnlijk niet zo lang meer hier wonen, maar 
voordat je vertrekt hoop ik je nog te zien schitteren tijdens je eigen verdediging! 
Gerard, Laura en Madelon, bedankt voor de welkome ontvangst bij jullie in de familie en 
de betrokkenheid bij mijn leven en werk.
Ik wil mijn ouders bedanken voor hun jarenlange steun. Als jongste in het gezin heb ik 
altijd veel mogelijkheden gekregen om dát te willen doen wat ik graag wilde. Jullie stonden 
altijd voor mij klaar. Lieve pap en mam, zonder jullie steun was ik nooit zo ver gekomen, 
heel erg bedankt! 
Geertje, toen ik nog jong was verliet je al het ouderlijk huis en vertrok je naar België om 
geneeskunde te gaan studeren. Onze werelden lagen ver uit elkaar. Toch hebben we 
uiteindelijk hetzelfde vak gekozen en hebben we meer overeenkomsten dan dat we ooit 
hadden gedacht. Ik kijk uit naar een promotie-plechtigheid in het Brusselse! 
Pieter, als grote broer ben je altijd belangrijk voor me geweest. Ik weet nog goed dat ik 
samen met Martine bij jou in Groningen kwam logeren voor de KEI-week. Wie had gedacht 
dat je tien jaar later aanwezig zou zijn bij de promotie van je zusje!? Kleine zusjes worden 
groot! 
Lieve Christiaan, je hebt het gevoel weinig te hebben bijgedragen aan dit proefschrift, 
ondanks dat je vaak je hulp hebt aangeboden. Ik heb je er inhoudelijk nooit bij willen 
betrekken, maar zonder jouw onvoorwaardelijke steun en vertrouwen in mijn kunnen was 102
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dit proefschrift er waarschijnlijk nooit gekomen. Met jou naast me haal ik het beste uit 
mezelf naar boven! Na een geweldige bruiloft afgelopen jaar en de promotie dit jaar, 
kunnen we ons nu na een heerlijke vakantie in alle rust voorbereiden op de komst van 
onze toekomstige spruit! 103
Curriculum vitae 
Irene Miedema is op 5 juli 1985 geboren in Franeker. In 2003 deed zij eindexamen 
gymnasium op het Christelijk Gymnasium Beyers Naudé te Leeuwarden. Aansluitend is zij 
begonnen met de studie Geneeskunde aan de Rijksuniversiteit Groningen waar zij in 2006 
haar Bachelor behaalde. In 2009 behaalde zij cum laude haar Master Geneeskunde. Tijdens 
de verschillende co-schappen ontstond de interesse in de neurologie en zij volgde 
uiteindelijk haar laatste co-schap als semi-arts op de afdeling Neurologie en Kinderneurologie 
van het Universitair Medisch Centrum Groningen. Aansluitend verrichte zij haar 
wetenschappelijke stage waar onder begeleiding van Gert-Jan Luijckx de basis voor dit 
proefschrift werd gelegd. In oktober 2009 is Irene gestart met de opleiding tot Neuroloog 
in het Universitair Medisch Centrum Groningen met als opleider Prof. Dr. H.P.H. Kremer. 
Zij hoopt in 2016 de opleiding tot Neuroloog af te ronden. 104
Prognostic factors of functional outcome in acute ischemic stroke
List of publications
Miedema I, Uyttenboogaart M, Koopman K, De Keyser J, Luijckx GJ. Statin use and 
functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke. 
Cerebrovasc Dis 2010 Feb;29(3):263-267. 
Miedema I, Horvath KM, Uyttenboogaart M, Koopman K, Lahr MM, De Keyser J, et al. 
Effect of selective serotonin re-uptake inhibitors (SSRIs) on functional outcome in patients 
with acute ischemic stroke treated with tPA. J Neurol Sci 2010 Jun 15;293(1-2):65-67.
 
Miedema I, Gosselt A, de Keyser J, Koopman K, Kremer B, Luijckx GJ, et al. Prior 
anticoagulant therapy, subtherapeutic international normalized ratio and thrombolytic 
therapy in acute ischemic stroke. Int J Stroke 2011 Dec;6(6):568-569. 
Miedema I, Luijckx GJ, De Keyser J, Koch M, Uyttenboogaart M. Thrombolytic therapy for 
ischaemic stroke in patients using warfarin: a systematic review and meta-analysis. J Neurol 
Neurosurg Psychiatry 2012 May;83(5):537-540. 
Miedema I, Uyttenboogaart M, Koch M, Kremer B, de Keyser J, Luijckx GJ. Lack of 
association between serum uric acid levels and outcome in acute ischemic stroke. J Neurol 
Sci 2012 Aug 15;319(1-2):51-55. 
Miedema I, Uyttenboogaart M, Luijckx GJ. Statin use and lipid profile in relation to safety 
and functional outcome after thrombolysis in ischemic stroke. Expert Rev Neurother 2012 
Aug;12(8):907-910. 
Miedema I, Luijckx GJ, Uyttenboogaart M. Bleeding risk with ischemic stroke therapy. 
JAMA 2012 Oct 3;308(13):1318-9; author reply 1319-20. 